



US 20100062462A1

(19) **United States**(12) **Patent Application Publication**
Badley et al.(10) **Pub. No.: US 2010/0062462 A1**(43) **Pub. Date: Mar. 11, 2010**(54) **IMMUNODEFICIENCY VIRUSES****Publication Classification**(76) Inventors: **Andrew D. Badley**, Rochester, MN
(US); **Gary D. Bren**, Chatfield, MN
(US); **Zilin Nie**, Rochester, MN
(US)

Correspondence Address:

FISH & RICHARDSON P.C.**PO BOX 1022****MINNEAPOLIS, MN 55440-1022 (US)**(51) **Int. Cl.**
G01N 33/53 (2006.01)
C07K 16/00 (2006.01)
C12N 9/96 (2006.01)
C12N 5/00 (2006.01)
C12Q 1/34 (2006.01)(52) **U.S. Cl. 435/7.92; 530/387.9; 530/391.3;**
435/188; 435/325; 435/346; 435/18(21) Appl. No.: **12/097,473**(22) PCT Filed: **Dec. 14, 2006**(86) PCT No.: **PCT/US06/48101**


§ 371 (c)(1),

(2), (4) Date: **Oct. 23, 2009**(30) **Foreign Application Priority Data**

Dec. 14, 2005 (US) 60/750653

(57) **ABSTRACT**

This document relates to methods and materials involved in detecting, monitoring, and prognosing immunodeficiency virus infections. For example, methods and materials for determining whether or not a mammal (e.g., a human) has an immunodeficiency virus infection (e.g., an HIV infection), methods and materials for determining whether or not a mammal with an immunodeficiency virus infection is improving, and methods and materials for determining whether or not a mammal with an immunodeficiency virus infection has an advanced immunodeficiency virus infection are provided.







Figure 1




Figure 2




Figure 2




Figure 2f





Figure 3

a



b





Figure 3

c



d




Figure 4




Figure 5





Figure 6

a



b





Figure 6

c



d




Figure 7a




Figure 7b




Figure 8

MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRK
QEPIKDALMLFQRLQEKRMLEESNLSFLKELLF
RINRLDLLITYLNTRKEEMERELQTPGRAQISAY
RVMLYQISEEVSRSELRSFKFLLQEEISKCKLDD
DMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKS
LLKIINDYEEFSKERSSSLEGSPDEFSSNGEELCG
VMTISDSPREQDSESQTLDKVYQMKSKPRGYC
LIINNHNFAKAREKVPKLHSIRDNRNGTHLDAGAL
TTTFEELHFEIKPHDDCTVEQIYEILKIYQLMDHS
NMDCFICCILSHGDKGIIYGTDGQEPPIYELTSQ
FTGLKCPSLAGKPKVFFIQACQGDNYQKGIPVE
TDSEEQPYLEMDLSSPQTRYIPDEADFLMGAT
VNNCVSYRNPAEGTWYIQSLCQSLRERCPRGD
DILTILTEVNIEVSNKDDKKNMGKQMPQPTFTL
RKKLVFSPD

Figure 9

MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQE
PIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRL
DLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQI
SEEVSRSELRSFKFLLQEEISKCKLDDDMNLLDIFIE
MEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFS
KERSSSLEGSPDEFSGEELCGVMTISDSPREQDS
ESQTLDKVYQMKS KPRGYCLIINNHNF AKAREKVP
KLHSIRDRNGTHLDAGALTTT FEELHFEIKPHDDCT
VEQIYEILKIYQLMDHSNMDCFICCILSHGDKGIYGT
DGQEPPIYELTSQFTGLKCPSLAGKPKVF

Figure 10

MKSQGQHWYSSSDKNCKVSFREKLLIIDSNLGVQ
DVENLKFLCIGLVPNKKLEKSSSASDVFEHLLAED
LLSEEDPFFLAELLYIIRQKKLLQHLNCTKEEVERL
LPTRQRVSLFRNLLYELSEGIDSENKDMIFLLKDS
LPKTEMTSLSFLAFLEKQGKIDEDNLTCLDLCKT
VVPKLLRNIEKYKREKAIQIVTPPVDKEAESYQGE
EELVSQTDVKTFLALPQESWQNKHAGSNGNRA
TNGAPSLVSRGMQGASANTLNSETSTKRAAVYR
MNRNHRGLCVIVNNHSFTSLKDRQGTHKDAEILS
HVFQWLGFTVHIHNNVTKVEMEMVLQKQKCNPA
HADGDCFVFCILTHGRFGAVYSSDEALIPREIMSH
FTALQCPRLAEKPKLFFIQACQGEEIQPSVSIEADA
LNPEQAPTSLQDSIPAEADFLGLATVPGYVSFRH
VEEGSWYIQSLCNHLKKLVPRHEDILSILTAVNDD
VSRRVDKQGTTKKQMPQPAFTLRKKLVFPVPLDAL
SL

Figure 11

MADEQGCIEEQGVEDSANEDSVDAKPDRSSFVP
SLFSKKKKKNVTMRSIKTTRDRVPTYQYNMNFEL
GKCIINNKNFDKVTGMGVRNGTDKDAEALFKCF
RSLGFDVIVYND CSCAKMQDLLKKASEEDHTNA
ACFACILLSHGEENVIIYGKDGVTPIKDLTAHFRGD
RCKTLLEKPKLFFIQACRGTELD DGIQADSGPIND
TDANPRYKIPVEADFLFAYSTVPGYYSWRSPGR
GSWFVQALCSILEEHGKDLEIMQILTRVND RVAR
HFESQSDDPHFHEKKQIPCVVSMLTKELYFSQ

Figure 12

MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQ
EPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINR
LDLLITYLNTRKEEMERELQTPGRAQISAYRWVET
PIVGLGGVG

Figure 13

MADDQGCIEEQGVEDSANEDSVDAKPDRSSF
VPSLFSKKKKKNVTMRSIKTTRDRVPTYQYNMN
FEKLGKCIINNKNFDKVTGMGVRNGTDKDAEA
LFKCFRSHGEENVIIYGKDGVTPIKDLTAHFRGD
RCKTLLEKPKLFFIQACRGTELDG IQADSGPIN
DTDANPRYKIPVEADFLFAYSTVPGYYSWRSP
GRGSWFVQALCSILEEHGKDLEIMQILTRVNDR
VARHFESQSDDPRFHEKKQIPCVVSMLTKELY
FSQ

Figure 14

MKSQGGQHWCS SSDKNCKVS FREKLLIDS NL
GVQDVENLKFLCIGLVPNKLLETSSSASDVFE
PFLAEDLLSEDDPFFLAELLYIIRQKKLLQHLNY
TKEEVERLLPTRQRVSLFRNLLYELSEGIDSE
NLKDMIFLLKDSL PKTEMTSLSFLAFLEKQGKI
DEDNLTCLEDLCTTVVPKLLRNIEKYKREKAV
QIVTPPVDKEAESYQGEEELVSQTDVKTFLEA
LPVGV LAK

IMMUNODEFICIENCY VIRUSES

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

[0001] This invention was made with government support under grant number AI62261 awarded by National Institutes of Health/National Institute of Allergy and Infectious Diseases. The government has certain rights in the invention.

BACKGROUND

[0002] 1. Technical Field

[0003] This document relates to methods and materials involved in detecting, monitoring, and prognosing immunodeficiency virus infections in mammals.

[0004] 2. Background Information

[0005] Although multiple stimuli associated with human immunodeficiency virus (HIV) infection are capable of resulting in T cell death, the mechanism by which HIV causes death of infected cells in vivo is unknown. It has been widely believed that bystander mechanisms of cell death are the principal cause of CD4⁺ T-cell depletion in patients with HIV infection. However, recent studies suggest that death of T cells in lymphoid tissues is due to direct cytotoxicity, viral cytopathicity, or lytic infection, rather than bystander cytotoxicity. Indeed, in both HIV-infected patients with acute disease and macaques acutely infected with simian immunodeficiency virus (SW), there is a rapid and profound destruction of virus containing activated memory CD4⁺/CCR5⁺ T cells in the gut that occurs within the first weeks of infection (Brenchley et al., *J. Exp. Med.*, 200:749-59 (2004); Mehandru et al., *J. Exp. Med.*, 200:761-70 (2004); Mattapallil et al., *Nature*, 434:1093-7 (2005); Li et al., *Nature*, 434:1148-52 (2005)).

SUMMARY

[0006] This document provides methods and materials related to detecting, monitoring, and prognosing immunodeficiency virus infections. For example, this document provides methods and Materials for determining whether or not a mammal (e.g., a human) has an immunodeficiency virus infection (e.g., an HIV infection), methods and materials for determining whether or not a mammal with an immunodeficiency virus infection is improving, and methods and materials for determining whether or not a mammal with an immunodeficiency virus infection has an advanced immunodeficiency virus infection. As described herein, cells infected with an immunodeficiency virus can express an immunodeficiency virus protease that cleaves a cellular caspase polypeptide (e.g., a caspase 8 polypeptide) to form a fragment (e.g., a casp8p41 polypeptide) of the cellular caspase polypeptide not normally detected in uninfected cells. Thus, the presence of such a fragment (e.g., a casp8p41 polypeptide) in cells from a mammal can indicate that that mammal has an immunodeficiency virus infection. In addition, the level of such a fragment in cells from a mammal can indicate the state (e.g., a mild, moderate, or severe state) of an immunodeficiency virus infection. Having the ability to detect, monitor, and prognose immunodeficiency virus infections can help clinicians provide appropriate medical treatments for infected individuals.

[0007] This document also provides methods and materials for assessing the effectiveness of anti-immunodeficiency virus infection treatments. For example, clinicians can deter-

mine whether or not an anti-immunodeficiency virus infection treatment is effective by assessing the level of an immunodeficiency virus protease-derived caspase polypeptide (IVP caspase polypeptide). Although not limited to any particular mode of action, an IVP caspase polypeptide can be generated via cleavage of a caspase polypeptide (e.g., a procaspase-8 polypeptide) by an immunodeficiency virus protease (e.g., an HIV protease). A p41 fragment of human caspase 8 (a casp8p41 polypeptide) is an example of an IVP caspase polypeptide. Assessing mammals with an immunodeficiency virus infection using the level of an IVP caspase polypeptide, rather than numbers of CD4⁺ T cells or number of virions, can allow clinicians to determine the effectiveness of therapies sooner.

[0008] This document also provides antibodies that can have the ability to bind to an IVP caspase polypeptide at a standard high affinity, while lacking the ability to bind to an uncleaved caspase polypeptide at that same affinity. Such antibodies can be used to detect an immunodeficiency virus infection (e.g., an HIV infection) in a mammal (e.g., a human).

[0009] In one embodiment, this document features an antibody preparation comprising an antibody or fragment thereof, where the antibody or the fragment thereof binds to a polypeptide consisting of a sequence selected from the group consisting of the sequence set forth in SEQ ID NO:2 and the sequence set forth in SEQ ID NO:3 and does not bind to a human procaspase-8 polypeptide. The antibody can be a monoclonal antibody. The antibody or the fragment thereof can comprise a label selected from the group consisting of an enzyme, streptavidin, avidin, a fluorescent molecule, a luminescent molecule, a bioluminescent molecule, and a radioactive molecule.

[0010] In another embodiment, this document features an isolated cell that produces an antibody or fragment thereof, where the antibody or the fragment thereof binds to a polypeptide consisting of a sequence selected from the group consisting of the sequence set forth in SEQ ID NO:2 and the sequence set forth in SEQ ID NO:3 and does not bind to a human procaspase-8 polypeptide. The isolated cell can be a hybridoma. The antibody can be a monoclonal antibody.

[0011] In another embodiment, this document features a method for determining whether or not a sample contains a casp8p41 polypeptide. The method comprises or consists essentially of: a) contacting the sample with an antibody or fragment thereof to form a complex between the casp8p41 polypeptide, if present in the sample, and the antibody or the fragment thereof, where the antibody or the fragment thereof binds to a polypeptide consisting of a sequence selected from the group consisting of the sequence set forth in SEQ ID NO:2 and the sequence set forth in SEQ ID NO:3 and does not bind to a human procaspase-8 polypeptide; and b) determining the presence or absence of the complex, where the presence indicates that the sample contains the casp8p41 polypeptide, and where the absence indicates that the sample does not contain the casp8p41 polypeptide. The sample can be blood. The determining step can comprise or consist essentially of performing an ELISA or flow cytometry.

[0012] In another embodiment, this document features a method for determining whether or not a treatment for an immunodeficiency virus infection decreases cell death. The method comprises or consists essentially of determining whether or not the level of an IVP caspase polypeptide in a first sample from a mammal infected with an immunodefi-

ciency virus is greater than or equal to the level of the IVP caspase polypeptide in a second sample from the mammal, where the first sample is from the mammal after the mammal received the treatment, where the second sample is obtained at a later time than the first sample, where a level of the IVP caspase polypeptide in the first sample that is equal to or greater than the level of the IVP caspase polypeptide in the second sample indicates that the treatment decreases cell death, and where a level of the IVP caspase polypeptide in the first sample that is lower than the level of the IVP caspase polypeptide in the second sample indicates that the treatment does not decrease cell death. The immunodeficiency virus can be a human immunodeficiency virus. The mammal can be a human. The IVP caspase polypeptide can be a casp8p41 polypeptide. The sample can be blood.

[0013] In another embodiment, this document features a method for monitoring an immunodeficiency virus infection. The method comprises or consists essentially of determining whether or not the level of an IVP caspase polypeptide in a first sample from a mammal infected with an immunodeficiency virus is greater than the level of the IVP caspase polypeptide in a second sample from the mammal, where the second sample is from the mammal at a time later than that of the first sample, where a level of the IVP caspase polypeptide in the first sample that is greater than the level of the IVP caspase polypeptide in the second sample indicates suppression of the infection, and where a level of the IVP caspase polypeptide in the first sample that is lower than the level of the IVP caspase polypeptide in the second sample indicates progression of the infection.

[0014] In another embodiment, this document features a method for determining the prognosis of an immunodeficiency virus infection. The method comprises or consists essentially of determining the level of an IVP caspase polypeptide in a mammal infected with an immunodeficiency virus, where a detectable level of the IVP caspase polypeptide indicates a poor prognosis, and where an undetectable level of the IVP caspase polypeptide indicates a good prognosis. The determining step can comprise or consist essentially of analyzing a sample from the mammal.

[0015] In another embodiment, this document features a method for detecting the presence of an immunodeficiency virus in a mammal. The method comprises or consists essentially of determining whether or not an IVP caspase polypeptide is present within a mammal, where a detectable level of an IVP caspase polypeptide indicates the presence of an immunodeficiency virus, and where an undetectable level of the IVP caspase polypeptide indicates the absence of an immunodeficiency virus. The determining step can comprise or consist essentially of analyzing a sample from the mammal.

[0016] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

[0017] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF THE DRAWINGS

[0018] FIG. 1A is a graph plotting the proteolytic cleavage of a fluorogenic gag-pol substrate in Jurkat T cells that were either mock-infected (Mock) or infected with HIV IIIB. The inset is an immunoblot of cytosol and membrane fractions probed with anti-LAT antibodies.

[0019] FIG. 1B is a schematic diagram of a nucleic acid molecule encoding a procaspase-8 polypeptide with an amino-terminal Flag epitope and a carboxyl-terminal Myc epitope. Death effector domains (DEDs) are conserved amino acid sequences important for protein-protein interactions with other DED-containing proteins. P18 and P10 are further cleavage products of procaspase-8, which are assembled to create the catalytically active heterodimer, (P18/P10)₂. "FF" refers to the site where HIV protease cleaves, between two phenylalanine residues.

[0020] FIG. 1C (top panel on left) is an autoradiograph of a gel separating reaction mixtures containing ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide incubated in the presence (PR) or absence (CTR) of HIV-1 protease. FIG. 1C (middle panel on left) is an immunoblot of ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide incubated in the presence (PR) or absence (CTR) of HIV-1 protease and probed with an anti-Flag antibody. FIG. 1C (bottom panel on left) is an immunoblot of ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide incubated in the presence (PR) or absence (CTR) of HIV-1 protease and probed with an anti-Myc antibody. FIG. 1C, right panel contains an autoradiograph of a gel separating reaction mixtures containing ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide incubated in the presence of HIV-1 protease or renin, or untreated.

[0021] FIG. 1D is an autoradiograph of a gel separating reaction mixtures containing wild-type procaspase-8 polypeptides or procaspase-8 polypeptides with mutations F355R and F356N incubated with the indicated amounts of HIV protease.

[0022] FIG. 2A contains a series of immunoblots of cytosolic extracts from Jurkat T cells that were mock-treated (CTR), or incubated with recombinant HIV protease (PR) or GST alone (GST), recombinant GST casp8p41 (casp8p41) or camptothecin (CPT). The cytosolic extracts were analyzed for Bid cleavage into p15 tBid, cytochrome c release into the cytosol, HSP70, and procaspase-9 cleavage.

[0023] FIG. 2B contains a series of photomicrographs of HeLa cells transfected with nucleic acid expressing GFP alone or GFPcasp8p41 and analyzed by confocal microscopy following DAPI and TUNEL staining. Camptothecin (CPT) treated cells and DNase I treated cells were included as controls.

[0024] FIGS. 2C and 2D contain histogram plots of data obtained from flow cytometric analyses of cells that were transfected with nucleic acid expressing GFP alone or GFPcasp8p41 and subjected to TUNEL staining (FIG. 2C, left panel), anti-active caspase-3 antibody staining (FIG. 2C, right panel), or Annexin-PE staining (FIG. 2D). The analyses were performed by gating on GFP-positive cells.

[0025] FIG. 2E contains a histogram plot and graph of data obtained from flow cytometric analyses of primary human T cells that were transfected with nucleic acid expressing GSK3 β or casp8p41 and analyzed for changes in viability by light scatter or for apoptosis by TUNEL staining.

[0026] FIG. 2F contains a series of immunoblots of cytosolic extracts from Jurkat T cells that were mock-treated (CTR), or incubated with recombinant HIV protease (HIV-1PR) or recombinant casp8p41 polypeptide (casp8p41). The cytosolic extracts were analyzed for Bid cleavage into p15 tBid, cytochrome c release into the cytosol, HSP70, procaspase-9 cleavage, and PARP cleavage.

[0027] FIG. 3A contains immunoblots of extracts from cells transfected with nucleic acid expressing GFP, GFP full-length (FL) caspase-8, GFPcasp8p43, or GFPcasp8p41 that were probed with anti-casp8p41 or anti-GFP antibodies.

[0028] FIG. 3B contains a series of photomicrographs of HeLa cells transfected with nucleic acid expressing GFPcasp8p41, GFP FL caspase-8, or GFPcasp8p43 and analyzed by immunofluorescence with a casp8p41 monoclonal antibody or an isotype control antibody and PE-labeled secondary anti-mouse immunoglobulin antibodies.

[0029] FIG. 3C is a graph plotting casp8p41 production in Jurkat T cells that were transfected with nucleic acid expressing HIV protease and mock-treated (0), treated with the HIV-PR inhibitor Nelfinavir (Nfv), or treated with the pancaspase inhibitor Z-VAD fmk (Z-VAD).

[0030] FIG. 3D is a graph plotting the percentage of Jurkat T cells treated with the indicated stimuli that was positive for active caspase-3 (black bars) and casp8p41 (grey bars), as analyzed by flow cytometry. For each condition, the number of caspase-3+ cells present in the buffer or vehicle control treated cells was subtracted from the cells treated with the apoptosis inducing agents.

[0031] FIG. 4A contains a series of histograms plots of flow cytometric data from Jurkat T cells acutely infected with HIV IIIB that were analyzed for p24 and casp8p41 polypeptides on the indicated days after infection.

[0032] FIG. 4B is a graph plotting the percent of HIV infected Jurkat T cells that were casp8p41 polypeptide positive and Trypan blue positive on the indicated days after infection.

[0033] FIG. 4C contains histogram plots of flow cytometric data from Jurkat T cells acutely infected with HIV and analyzed for p41 polypeptide positivity and TUNEL staining 7 days after infection. Analyses were performed after gating on casp8p41 polypeptide negative cells (left panel) or casp8p41 polypeptide positive cells (right panel).

[0034] FIG. 5A is an immunoblot analyzing the expression of procaspase 8 in I9.2 cells that were mock-transfected, or stably transfected with either wild-type procaspase 8 (WT casp8) or procaspase 8 containing the F355R, F356N mutations (casp8 RN).

[0035] FIG. 5B is a graph plotting the percentage of viable I9.2 cells stably transfected with wild-type procaspase 8 (WT casp8) or procaspase 8 containing the F355R, F356N mutations (casp8 RN) and infected with VSV-G pseudotyped HIV. Viability was assessed as a function of time using Trypan blue.

[0036] FIG. 5C is a graph plotting the relative cell number of I9.2 cells stably transfected with wild-type procaspase 8 (WT casp8) or procaspase 8 containing the F355R, F356N

mutations (casp8 RN) at 60 hours post-infection with VSV-G pseudotyped HIV. The relative cell number was measured based on ATP activity.

[0037] FIG. 5D is a graph plotting casp8p41 production in I9.2 cells stably transfected with wild-type procaspase 8 (WT casp8) or procaspase 8 containing the F355R, F356N mutations (casp8 RN) at 60 hours post-infection with VSV-G pseudotyped HIV. Results are representative of two independent experiments.

[0038] FIG. 6A is a graph plotting the percentage of casp8p41 positive cells in peripheral blood lymphocytes from HIV infected patients versus the viral load.

[0039] FIG. 6B contains a series of histogram plots of flow cytometric data analyzing peripheral blood lymphocytes from HIV-infected patients or uninfected donors for p24 polypeptide, casp8p41 polypeptide, and active caspase-3 polypeptide positivity.

[0040] FIG. 6C is a graph plotting the HIV viral load versus the percentage of p24 polypeptide positive cells that are positive for casp8p41 polypeptide.

[0041] FIG. 6D contains dot plots analyzing casp8p41, CD3, CD4, CD8, CD27, CD45RO, CD14, and CD19 expression in CD4⁺ T cells. Casp8p41 positive cells (red) were assessed for CD27 and CD45RO expression and compared to casp8p41 negative CD4 T cells.

[0042] FIG. 7A contains a series of photomicrographs of freshly frozen lymph nodes from HIV-negative donors or from HIV-infected patients being treated or not being treated with highly active antiretroviral therapy (HAART) that were analyzed by confocal microscopy after staining with anti-p24 polypeptide and anti-casp8p41 polypeptide antibodies and DAPI.

[0043] FIG. 7B contains a series of photomicrographs of lymph node sections similar to those in FIG. 7A that were analyzed for casp8p41 polypeptide, active caspase-3 polypeptide, and DAPI staining by confocal microscopy.

[0044] FIG. 8 is a listing of an amino acid sequence of a human caspase 8 polypeptide (SEQ ID NO:1).

[0045] FIG. 9 is a listing of an amino acid sequence of a human casp8p41 polypeptide (SEQ ID NO:2).

[0046] FIG. 10 is a listing of an amino acid sequence of a human caspase 10 polypeptide (SEQ ID NO:5).

[0047] FIG. 11 is a listing of an amino acid sequence of a human caspase 7 polypeptide (SEQ ID NO:6).

[0048] FIG. 12 is a listing of an amino acid sequence of a chimpanzee caspase 8 polypeptide (SEQ ID NO:7).

[0049] FIG. 13 is a listing of an amino acid sequence of a chimpanzee caspase 7 polypeptide (SEQ ID NO:8).

[0050] FIG. 14 is a listing of an amino acid sequence of a chimpanzee caspase 10 polypeptide (SEQ ID NO:9).

DETAILED DESCRIPTION

[0051] This document provides methods and materials involved in identifying, monitoring, and prognosing immunodeficiency virus infections (e.g., HIV infections). For example, this document provides methods and materials for determining whether or not a mammal (e.g., a human) has an immunodeficiency virus infection (e.g., an HIV infection), methods and materials for determining whether or not a mammal with an immunodeficiency virus infection is improving, and methods and materials for determining whether or not a mammal with an immunodeficiency virus infection has an advanced immunodeficiency virus infection. This document also provides methods and materials for assessing the effec-

tiveness of anti-immunodeficiency virus infection treatments. In addition, this document provides antibodies having the ability to bind to an IVP caspase polypeptide at a standard high affinity, while lacking the ability to bind to an uncleaved caspase polypeptide at that same affinity.

[0052] As described herein, this document provides methods and materials for identifying mammals having an immunodeficiency virus infection. Any mammal can be identified as having an immunodeficiency virus infection. For example, a human, a cat, or a monkey can be identified as having an immunodeficiency virus infection. In addition, any human can be identified as having an immunodeficiency virus infection. For example, an infant, a child, an adult, or a senior citizen of any race or gender can be diagnosed as having an immunodeficiency virus infection using the methods and materials provided herein.

[0053] An immunodeficiency virus can be any retrovirus causing immunosuppression, such as a human immunodeficiency virus (HIV), a feline immunodeficiency virus (FIV), or a simian immunodeficiency virus (SIV). In addition, an immunodeficiency virus can be any type of immunodeficiency virus, such as HIV type O, HIV type 1, or HIV type 2.

[0054] In some embodiments, a mammal can be identified as being infected with an immunodeficiency virus if it is determined that a sample (e.g., a blood or a lymph node sample) from the mammal contains an IVP caspase polypeptide.

[0055] The term "IVP caspase polypeptide" as used herein refers to any polypeptide with the same amino acid sequence as a polypeptide fragment that can be formed from a cellular caspase polypeptide via cleavage by an immunodeficiency virus protease. For example, an IVP caspase polypeptide can be any polypeptide with the same amino acid sequence as a polypeptide fragment that formed from any cellular caspase polypeptide via cleavage by any immunodeficiency virus protease. Examples of cellular caspase polypeptides include, without limitation, human caspase 8 polypeptides, feline caspase 8 polypeptides, simian caspase 8 polypeptides, human caspase 10 polypeptides, feline caspase 10 polypeptides, simian caspase 10 polypeptides, human caspase 7 polypeptides, feline caspase 7 polypeptides, and simian caspase 7 polypeptides. The amino acid sequence of a human caspase 8 polypeptide can be as set forth in FIG. 8 and SEQ ID NO:1. The amino acid sequence of a simian caspase 8 polypeptide can be as set forth in FIG. 12 and SEQ ID NO:7. The amino acid sequence of a human caspase 10 polypeptide can be as set forth in FIG. 10 and SEQ ID NO:5. The amino acid sequence of a simian caspase 10 polypeptide can be as set forth in FIG. 14 and SEQ ID NO:9. The amino acid sequence of a human caspase 7 polypeptide can be as set forth in FIG. 11 and SEQ ID NO:6. The amino acid sequence of a simian caspase 7 polypeptide can be as set forth in FIG. 13 and SEQ ID NO:8. Examples of immunodeficiency virus proteases include, without limitation, HIV proteases, FIV proteases, and SIV proteases. An example of an IVP caspase polypeptide is a casp8p41 polypeptide, which can be generated via cleavage of a human procaspase-8 polypeptide by an HIV protease. The amino acid sequence of a casp8p41 polypeptide can be as set forth in FIG. 9 and SEQ ID NO:2. In some cases, an IVP caspase polypeptide can be a polypeptide generated via cleavage of a feline caspase polypeptide by an FIV protease. In some cases, an IVP caspase polypeptide can be a polypeptide generated via cleavage of a simian caspase polypeptide by an SW protease.

[0056] In some cases, a FLIP polypeptide fragment formed from a FLIP polypeptide via cleavage by an immunodeficiency virus protease can be used either (1) alone in place of an IVP caspase polypeptide, or (2) in combination with an IVP caspase polypeptide, to detect, monitor, and/or prognose immunodeficiency virus infections in mammals. An example of a nucleic acid encoding a human FLIP polypeptide is set forth in SEQ ID NO:15 and GenBank Accession No. NM_003879. An amino acid sequence of a human FLIP polypeptide can be as set forth in SEQ ID NO:16 and GenBank Accession No. NM_003879. In some cases, FLIP polypeptide fragments can be formed via cleavage of a FLIP polypeptide between amino acid residues corresponding to residues 355 and 356 of the amino acid sequence set forth in SEQ ID NO:16. A FLIP polypeptide fragment formed from a FLIP polypeptide via cleavage by an immunodeficiency virus protease can be used to generate anti-FLIP fragment antibodies. Such anti-FLIP fragment antibodies can be used to detect FLIP fragments in cells from a mammal. The presence of FLIP fragments (e.g., those FLIP fragments having a C-terminus corresponding to amino acid residue 355 of SEQ ID NO:16, or an N-terminus corresponding to amino acid residue 356 of SEQ ID NO:16) in a mammal can indicate that the mammal has an immunodeficiency virus infection.

[0057] Any method can be used to obtain a biological sample for evaluation. For example, blood can be obtained by peripheral venipuncture and evaluated for an IVP caspase polypeptide. In some cases, serum or plasma can be prepared from the blood and evaluated for an IVP caspase polypeptide. In some cases, lymphocytes can be isolated from peripheral blood using standard techniques, such as Ficoll-Hypaque density gradient separation, and evaluated for an IVP caspase polypeptide.

[0058] One or more samples can be collected from a mammal (e.g., a human) at one or more time points and evaluated for an IVP caspase polypeptide (e.g., a casp8p41 polypeptide). For example, a sample can be collected from an individual on a regular basis (e.g., every week, every two weeks, every month, every two months, every three months, every six months, or every year) and evaluated for a casp8p41 polypeptide. The frequency of sample collection and evaluation for an IVP caspase polypeptide also can vary over time. The levels of an IVP caspase polypeptide in multiple samples from the same mammal obtained at various times can be compared. Such a comparison can indicate, for example, the onset of an immunodeficiency virus infection or the progression of an immunodeficiency virus infection.

[0059] Once a biological sample, such as a blood or tissue sample, is obtained, the sample can be evaluated for an IVP caspase polypeptide. Alternatively, a biological sample can be divided into aliquots, preserved (e.g., fixed or frozen), and stored for analysis at a later time. For example, a sample can be frozen at a temperature of -20°C . or lower (e.g., -25°C ., -75°C ., -80°C ., -100°C ., or -200°C .) and stored frozen for days, months, or years. A frozen sample can be thawed and evaluated for an IVP caspase polypeptide. In some cases, a biological sample, such as a tissue specimen, can be formaldehyde-fixed and paraffin-embedded, sectioned, and stored at room temperature for days, months, or years prior to being evaluated for an IVP caspase polypeptide.

[0060] Any method can be used to determine the level of an IVP caspase polypeptide in a biological sample. For example, the level of an IVP caspase polypeptide in a biological sample can be determined using, without limitation, ELISA, radio-

immunoassay, fluoroimmunoassay, Western blotting, flow cytometry, immunohistochemistry, immunoprecipitation, confocal microscopy, or mass spectrometry.

[0061] In some embodiments, the methods and materials provided herein can be used to identify mammals as being infected with an immunodeficiency virus in cases where serologic assays can be unreliable. For example, the methods and materials provided herein can be used at a stage before seroconversion to identify a mammal as being infected with an immunodeficiency virus. In some cases, the methods and materials provided herein can be used to identify a mammal having an acute immunodeficiency virus infection. The methods and materials provided herein also can be used to identify a child infected with an immunodeficiency virus through the route of maternal fetal transmission.

[0062] This document also provides methods and materials for monitoring the course of an immunodeficiency virus infection (e.g., an HIV infection) in a mammal (e.g., a human). For example, the course of an HIV infection can be monitored by comparing the level of a casp8p41 polypeptide in a sample from an individual to the level of a casp8p41 polypeptide in a second sample obtained from the same individual at an earlier point in time. In some cases, a measurable increase in the amount of a casp8p41 polypeptide in a sample from an individual relative to the amount of a casp8p41 polypeptide in a second sample from the same individual taken at an earlier time point (e.g., one week, two weeks, a month, two months, six months, one year, two years, or five years earlier) can indicate progression of the HIV infection. In some cases, a measurable decrease in the amount of a casp8p41 polypeptide in a sample from an individual relative to the amount of a casp8p41 polypeptide in a second sample from the same individual taken at an earlier time point (e.g., one week, two weeks, a month, two months, six months, one year, two years, or five years earlier) can indicate suppression of the HIV infection. For example, a measurable decrease in the amount of a casp8p41 polypeptide in a sample from an individual relative to the amount of a casp8p41 polypeptide in a second sample from the same individual taken at an earlier time point (e.g., one week, two weeks, a month, two months, six months, one year, two years, or five years earlier) can indicate reduced HIV replication.

[0063] Samples collected from the same mammal (e.g., human) at different time points can be preserved and stored, as described above, so that they can be evaluated simultaneously. Alternatively, the samples can be analyzed individually, e.g., at their respective times of collection, and the IVP caspase polypeptide levels of samples analyzed at later time points can be compared to the IVP caspase polypeptide levels of samples analyzed at earlier time points.

[0064] Samples also can be divided into aliquots once they are collected, and an aliquot of each sample can be analyzed at each time point for an IVP caspase polypeptide.

[0065] The course of an immunodeficiency virus infection in a mammal can be monitored on a regular basis (e.g., every week, every two weeks, every month, every two months, every three months, every six months, or every year) or on an irregular basis over the course of weeks, months, years, or a lifetime. In addition, the course of an immunodeficiency virus infection can be monitored in any mammal infected with an immunodeficiency virus. For example, the course of an HIV infection can be monitored in an HIV infected infant, child, adult, or senior citizen of any race or gender.

[0066] This document also provides methods and materials for assessing the effectiveness of an immunodeficiency virus (e.g., HIV) treatment, such as highly active antiretroviral therapy (HAART), in a mammal (e.g., a human) infected with an immunodeficiency virus. For example, the effectiveness of an immunodeficiency virus treatment can be assessed by comparing the level of an IVP caspase polypeptide (e.g., a casp8p41 polypeptide) in one sample from a mammal having received the treatment to the level of an IVP caspase polypeptide in another sample obtained from the same mammal at an earlier time point. In some cases, a measurable decrease in the amount of an IVP caspase polypeptide in a sample from a mammal having received an immunodeficiency virus treatment relative to the amount of an IVP caspase polypeptide in an earlier obtained sample from the same mammal (e.g., a sample obtained one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, one month, two months, six months, one year, two years, five years, seven years, or ten years earlier) can indicate that the immunodeficiency virus treatment is effective. In some cases, a measurable increase in the amount of an IVP caspase polypeptide in a sample from a mammal having received an immunodeficiency virus treatment relative to the amount of an IVP caspase polypeptide in an earlier obtained sample from the same mammal (e.g., a sample obtained one day, two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, one month, two months, six months, one year, two years, five years, seven years, or ten years earlier) can indicate that the immunodeficiency virus therapy is not effective. The earlier obtained sample collected from the mammal can be collected during or prior to treatment of the mammal with an immunodeficiency virus therapy. For example, the earlier obtained sample can be collected one, two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or more days before treatment of the mammal with an immunodeficiency virus therapy. The sample collected subsequent to collection of the earlier obtained sample can be collected during or following treatment of the mammal having an immunodeficiency virus infection.

[0067] Any number of samples collected from a mammal having an immunodeficiency virus infection at two or more time points can be evaluated for IVP caspase polypeptide levels to monitor the effectiveness of an immunodeficiency virus therapy. For example, samples obtained from a mammal prior to receiving an immunodeficiency virus therapy and once a week for one year during treatment can be used to monitor the effectiveness of an immunodeficiency virus treatment. Comparing the levels of an IVP caspase polypeptide in the samples can indicate whether or not the therapy is effective. For example, a decrease in the level of an IVP caspase polypeptide over time can indicate that the therapy is effective. In some cases, a lack of a decrease (e.g., an increase) in the level of an IVP caspase polypeptide over time can indicate that the therapy is not effective. In some cases, a decrease in the level of an IVP caspase polypeptide over an initial time period followed by an increase in the level of an IVP caspase polypeptide can indicate that the therapy is no longer effective, possibly due to viral resistance to the therapy.

[0068] The effectiveness of an immunodeficiency virus (e.g., HIV) therapy can be assessed in any mammal (e.g.,

human) having an immunodeficiency virus infection and having received an immunodeficiency virus therapy. For example, the effectiveness of an HIV therapy can be assessed in an infant, a child, an adult, or a senior citizen of any race or gender having an HIV infection and having received an HIV therapy.

[0069] This document also provides methods for determining prognosis in immunodeficiency virus (e.g., HIV) infection. For example, the prognosis of a mammal (e.g., a human) infected with an immunodeficiency virus (e.g., HIV) can be determined by determining the level of an IVP caspase polypeptide (e.g., a casp8p41 polypeptide) in a sample (e.g., a sample comprising CD4⁺ cells) from the mammal. In some cases, the presence of an IVP caspase polypeptide in a sample from a mammal can indicate a rapid depletion of CD4⁺ cells and, therefore, a poor prognosis. In some cases, the absence of a detectable level of an IVP caspase polypeptide in a sample from a mammal can indicate a slow depletion of CD4⁺ cells and, therefore, a good prognosis.

[0070] In some cases, the level of an IVP caspase polypeptide can be measured in addition to the level of another polypeptide, and the ratio of the levels can be used to determine a mammal's prognosis. For example, a ratio of an IVP caspase polypeptide to an immunodeficiency virus p24 polypeptide can be used to determine a mammal's prognosis. Any method can be used to determine the level of an immunodeficiency virus (e.g., HIV) p24 polypeptide in a biological sample. For example, an ELISA (Beckman Coulter, Brea, Calif.) can be used to measure the level of an HIV p24 polypeptide in serum or plasma.

[0071] The prognosis of a mammal infected with an immunodeficiency virus also can be determined by measuring the level of an IVP caspase polypeptide in a sample from the mammal and determining the mammal's CD4⁺ cell count. For example, an undetectable level of an IVP caspase polypeptide coupled with a CD4⁺ cell count greater than 500 CD4⁺ cells/mm³, e.g., greater than 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550; or 1600 CD4⁺ cells/mm³, can indicate a good prognosis. Determining the prognosis of a mammal infected with an immunodeficiency virus can allow clinicians to design the most appropriate therapeutic strategies. For example, an HIV patient having a poor prognosis may warrant a more aggressive treatment strategy and vice versa.

[0072] Any method can be used to determine a mammal's CD4⁺ cell count. For example, absolute CD4⁺ cell counts can be determined based on immunophenotypic identification of cells with fluorescently labeled monoclonal antibodies directed against the CD4 antigen. Relative percentages of CD4⁺ T cells can be determined with a flow cytometer. An absolute CD4⁺ cell count can be derived by multiplying the percentage of lymphocytes that are CD3⁺/CD4⁺ by the absolute lymphocyte count determined with a hematology instrument. Alternatively, TruCount Absolute Count Tubes (BD Biosciences, San Jose, Calif.) can be used to measure CD4⁺ cell levels in HIV-infected patients.

[0073] This document also provides antibodies that bind to an IVP caspase polypeptide. Such antibodies can have the ability to bind to an IVP caspase polypeptide at an affinity of at least 10⁴ mol⁻¹, e.g., at least 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, or 10¹² mol⁻¹, while lacking the ability to bind to an uncleaved version of the cellular IVP caspase polypeptide corresponding to the IVP caspase polypeptide at that affinity. For example, an antibody provided herein can have the ability

to bind to human casp8p41 at an affinity of at least 10⁴ mol⁻¹, e.g., at least 10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹² mol⁻¹, while lacking the ability to bind to an uncleaved human caspase 8 polypeptide at that affinity. In some cases, the antibody can bind to an IVP caspase polypeptide at an affinity between 10⁴ to 10¹³ mol⁻¹, 10⁴ to 10¹² mol⁻¹, 10⁴ to 10¹¹ mol⁻¹, 10⁴ to 10¹⁰ mol⁻¹, 10⁵ to 10¹³ mol⁻¹, 10⁵ to 10¹² mol⁻¹, 10⁵ to 10¹¹ mol⁻¹, 10⁵ to 10¹⁰ mol⁻¹, 10⁶ to 10¹³ mol⁻¹, 10⁶ to 10¹² mol⁻¹, 10⁶ to 10¹¹ mol⁻¹, or 10⁶ to 10¹⁰ mol⁻¹. In some cases, the antibody can bind to an IVP caspase polypeptide at a concentration of 0.05 to 1.0 µg/mL (e.g., 0.1 to 0.5 µg/mL, 0.1 to 0.4 µg/mL, or 0.08 to 0.8 µg/mL) without observable cross-reactivity to an uncleaved version of the IVP caspase polypeptide via flow cytometry or immunofluorescence. In some cases, an antibody provided herein can bind to a casp8p41 polypeptide (e.g., SEQ ID NO:2), a polypeptide corresponding to the carboxy terminal end of a casp8p41 polypeptide (e.g., SEQ ID NO:3), or a polypeptide comprising the four carboxy terminal amino acids of a casp8p41 polypeptide (e.g., SEQ ID NO:4), as determined by immunoassays well known in the art for assaying antibody-antigen binding.

[0074] The term "antibody" as used herein includes, without limitation, polyclonal, monoclonal, multi-specific, human, humanized, chimeric, and single-chain antibodies as well as antibody fragments having binding activity such as Fab fragments, F(ab') fragments, F(ab')₂ fragments, Fd fragments, fragments produced by a Fab expression library, fragments comprising a VL or VH domain, and epitope binding fragments of any of the above. An antibody can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. In addition, antibodies can be from any animal including birds and mammals. For example, antibodies can be human, murine, rabbit, goat, guinea pig, camel, horse, or chicken.

[0075] An antibody can be naturally occurring, recombinant, or synthetic. Antibodies can be generated by any suitable method known in the art. For example, monoclonal antibodies can be prepared using a wide variety of techniques known in the art, including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. An antibody such as an antibody fragment can be produced by any means. For example, an antibody fragment can be enzymatically or chemically produced by fragmentation of an intact antibody. An antibody fragment can also be produced synthetically or recombinantly from a gene encoding the partial antibody sequence.

[0076] Once an antibody has been produced by an animal, chemically synthesized, or recombinantly expressed, it can be purified by any method known in the art. For example, an antibody can be purified by chromatography, centrifugation, or differential solubility. In some cases, an antibody can be fused to a sequence, such as a hexa-histidine peptide, for convenient purification of the fusion protein. A substantially pure preparation of an antibody can be enriched for the antibody. For example, a substantially pure antibody preparation can be enriched such that 20, 30, 40, 50, 60, 70, 80, 90, or 100% of the antibodies present in the preparation are identical.

[0077] Antibodies provided herein can be used, without limitation, to purify or detect an IVP caspase polypeptide (e.g., a casp8p41 polypeptide). For example, the antibodies can be used in immunoassays for qualitatively and quantitatively measuring levels of casp8p41 polypeptides in biologi-

cal samples (e.g., blood samples). The antibodies can be recombinantly fused or conjugated to molecules useful as labels in detection assays, such as enzymes, streptavidin, avidin, fluorescent molecules, luminescent molecules, bioluminescent molecules, and radioactive molecules. A detectable substance can be coupled or conjugated either directly to the antibody or fragment thereof, or indirectly, e.g., through a linker. In some cases, an antibody can be fused to another molecule (e.g., a polypeptide) to aid in the uptake of the antibody into cells. See, e.g., Mie et al., *Biochem. Biophys. Res. Comm.*, 310(3): 730-734 (2003).

[0078] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1

Detecting HIV Protease Activity in HIV-Infected Cells

[0079] HIV protease activity was assessed during HIV infection to determine whether the protease was active in the cytosolic compartment and the membrane fraction. Jurkat T cells were infected with HIV, the cytosolic and membrane fractions were separated, and the purity was confirmed by analysis of the membrane-specific marker LAT using immunoblotting (FIG. 1A, inset; Tridandapani et al., *J Biol Chem*, 275:20480-20487 (2000)). Each fraction was assessed for protease activity using a fluorogenic gag-pol substrate.

[0080] To directly measure the protease activity in the cytoplasmic compartment of the infected cells, 200×10^6 HIV-infected Jurkat cells were harvested when the infected cells started to die (typically at day three or four post-infection). The harvested cells were washed twice to remove the cell surface attached virus particles, and were then resuspended in swelling buffer (10 mM Tris-HCl, pH 7.4, 5 mM MgCl₂, 30 mM NaCl, 1 mM EGTA, 1 mM DTT, 100 mM PMSF, 10 μ g/mL leupeptin, 2 μ g/mL aprotinin). After incubation on ice for 15 minutes, the cells were disrupted with 30 strokes of a tight-fitting "B" type glass Dounce homogenizer. The nuclei and subcellular organelles were removed by centrifugation at 10,000 rpm for 30 minutes at 4° C. The supernatant from this spin was further centrifuged for one hour at 100,000 $\times$ g using a Beckman Rotor SW Ti55 with 2 mL Quick-Seal centrifuge tubes. The resulting supernatant (S100) was collected as cytosolic fraction and the pellet, membrane fraction, was suspended with 500 μ L of the swelling buffer supplemented with 0.1% Triton $\times$ 100. The same numbers of uninfected Jurkat cells were processed in parallel according to the same protocol. The protease activities were measured using equivalent amounts of proteins from both the cytosolic fractions (S-100) and the membrane fractions using a fluorogenic substrate, as we described elsewhere (Cuerrier et al., *Biochem Biophys Res Commun.*, 327:208-211 (2005)).

[0081] The membrane fraction of HIV-infected cells contained more protease activity than the membrane fraction of uninfected cells ($P=0.0047$; FIG. 1A).

[0082] Moreover, the cytosolic fraction of HIV-infected cells contained significantly more protease activity than uninfected cells ($P=0.0378$; FIG. 1A). These results indicate that HIV protease is active in the cytoplasm of infected T cells.

These results also indicate that protease cleavage of cytosolic host cell proteins may contribute to viral cytopathicity.

Example 2

Identifying the Site of Cleavage of Procaspase-8 by HIV Protease

[0083] To identify the site of cleavage of procaspase-8 by HIV protease, a procaspase-8 expression construct was constructed with an amino terminal Flag epitope and a carboxyl terminal Myc epitope (FIG. 1B). The following primers were used to amplify a Flag-procaspase-8-Myc fragment from a pcDNA3procaspase8 plasmid using the polymerase chain reaction (PCR): 5'CCCAAGCTTATGGACTACAAAGACGATGACGGTACCATGGACTTCAG C-3' (Flag_sense; SEQ ID NO:10), and 5'-CCGGGCCCTTACTACAGATCCTCTCTGAGATGAGTTTTTGTCTCTA-GATTGATCAGAAAGGAAAA G-3' (Myc_antisense; SEQ ID NO:11). The Flag-procaspase-8-Myc fragment from the PCR was inserted back into HindIII and XbaI sites of the pcDNA3 vector, and the resulting construct was designated pcDNA3Flag-procaspase-8-Myc.

[0084] The fusion polypeptide, Flag-procaspase-8-Myc, was prepared by TNTR Quick coupled transcription/translation systems (Promega, Madison, Wis.). Briefly, 1 μ g of pcDNA3Flag-procaspase-8-Myc or pcDNA3Flag (as a control) was added to a 50 μ L nuclease-free reaction mixture containing 40 μ L of TNT Quick Master Mix and 1 μ L of 1 mM ³⁵S methionine. The reaction was carried out at 30° C. for 90 minutes and stopped by adding 20 μ g/mL of cycloheximide (CI-IX) and 200 μ g/mL of RNase and incubating the mixture at 30° C. for 5 minutes. ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide was prepared by adding 40 μ Ci of ³⁵S methionine instead of 1 μ L of 1 mM methionine. The reaction mixture was separated by SDS-PAGE on a 10-15% gel and visualized by autoradiography. IVTT products were cleaned using a G50 Column (Amersham Biosciences, Piscataway, N.J.), and reconstituted in caspase buffer (25 mM HEPES, pH 7.5, 0.15 M NaCl, 5 mM DTT, 10% sucrose).

[0085] The ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide produced in vitro was incubated with HIV-1 protease purchased from Sachem Biosciences (King of Prussia, Pa.). The HIV-1 protease had a specific activity of 1.81×10^4 mM/min./mg at 37° C. and a purity of greater than 96 percent by SDS-PAGE. RP-HPLC analysis of the HIV-1 protease produced a single peak. HIV-1 protease assays were performed in a buffer containing 50 mM NaOAc (pH 4.9), 200 mM NaCl, 5 mM DTT, and 10% glycerol. After cleavage of ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide by HIV-1 protease, the products were analyzed by autoradiography (FIG. 1C, top) and immunoblotting using antibodies directed against the Flag (FIG. 1C, middle) and Myc (FIG. 1C, bottom) epitopes. HIV-protease cleavage of ³⁵S methionine-labeled Flag-procaspase-8-Myc fusion polypeptide resulted in a predominant band containing a Flag epitope. These results suggested that the cleavage site was located within the carboxyl terminal half of the p18 subunit of procaspase-8. In contrast, another aspartyl protease, renin, did not cause procaspase 8 cleavage (FIG. 1C, right panel).

[0086] Highly purified procaspase-8 p18 subunit was cleaved with HIV protease, and the resultant cleavage products were sequenced by mass spectroscopy following tryptic digestion. The recombinant active caspase-8 was purchased

from R & D Systems (Minneapolis, Minn.). After cleavage by HIV-1 protease, the products were separated by SDS-PAGE and stained using silver stain plus (Bio-Rad, Hercules, Calif.). The silver stained bands were digested with trypsin, and the extracted peptides were analyzed by LC-tandem mass spectrometry.

[0087] A Waters Micromass Q-T of API-US quadrupole time-of-flight mass spectrometer with a Z-spray ESI source was coupled to a CapLC HPLC system (Waters, Milford, Mass.). Both instruments were controlled by MassLynx 4.0. HPLC was carried out by running a gradient of increasing acetonitrile in 0.1% formic acid on a Vydac C4 column (300 $\mu\text{m} \times 100 \text{ mm}$) at a flow rate of 4 $\mu\text{L}/\text{min.}$, and eluting directly into the mass spectrometer. The mass spectrometry experiment consisted of continuous 2 second scans of 400-2000 m/z , and the spectra were deconvoluted using the MassLynx MaxEnt algorithm to give monoisotopic masses.

[0088] Tryptic digestion of the procaspase-8 p18 subunit generated three specific peptides: RGYCLIINHNFAK (N-terminal; SEQ ID NO:12), KGI-IYGTGQEQAPIYELTSQFTGLK (SEQ ID NO:13), and KVFFIQACQGDNYQK (C-terminal; SEQ ID NO:14). When the procaspase-8 p18 subunit was digested with HIV protease prior to digesting with trypsin, the tryptic peptide KVFFIQACQGDNYQK (C-terminal; SEQ ID NO:14) was lost.

[0089] These results indicated that the cleavage site for HIV protease resides within the C-terminal tryptic fragment. To define the precise cleavage site for HIV protease, the molecular weight of the cleaved p18 fragment was measured by LC-MS. The sample of procaspase-8 p18 cleaved by HIV protease had a fragment that was not present in the sample of procaspase-8 p18 that was not cleaved by HIV protease. This fragment had a weight of 16158 mass units (cleaved form), indicating that procaspase-8 p18 was cleaved by HIV protease between Phe355 and Phe356.

[0090] To confirm this result, amino acids 355 and 356 were mutated in full-length caspase-8 to reduce the likelihood of HIV protease cleavage at that site. Mutations were selected based on a Markov chain model of HIV protease substrate cleavage (Chou, *Anal Biochem.*, 233:1-14 (1996); Chou and Zhang, *J Protein Chem.*, 12:709-724 (1993)). The wild-type octapeptide surrounding amino acids 355/356 was predicted to be cleaved by HIV protease with high efficiency, whereas the F355R, F356N mutation was predicted to be cleaved much less efficiently. Phe355 and Phe356 were replaced with Arg355 and Asn356, respectively, in plasmid pcDNA3Flag-procaspase-8-Myc using the QuikChange® site-directed mutagenesis kit (Stratagene, La Jolla, Calif.). ^{35}S -methionine labeled wild-type procaspase-8 and the mutant procaspase-8 F355R, F356N were reacted with HIV protease and analyzed for cleavage by autoradiography. Incubation of wild-type procaspase-8 with HIV protease resulted in a p41 procaspase-8 fragment. In contrast, an almost negligible amount of cleavage was observed when procaspase-8 F355R, F356N was incubated with HIV protease (FIG. 1D).

Example 3

Determining that casp8p41 Polypeptide Causes Apoptosis

[0091] The ability of the procaspase-8 cleavage fragment p41 (hereafter referred to as casp8p41) to initiate an apoptotic signaling cascade in a cell-free system was tested. The cell

free system was used previously to reveal the signaling pathway used by HIV protease to initiate apoptosis.

[0092] Jurkat cells were purchased from ATCC (Rockville, Md.) and maintained in Dulbecco's Modified Eagle Medium (DMEM) or RPMI1640 (GIBCO) supplemented with 10% (v/v) FBS, 1% penicillin and streptomycin, and 2 mM L-glutamine. The cells were incubated at 37° C. in a humidified atmosphere containing 5% CO_2 and 95% air. Jurkat cell extracts were prepared as described previously (Nie et al., *Cell Death Differ.*, 9:1172-84 (2002)). Briefly, cells (0.5×10^6 cells/mL) were harvested by centrifugation at 16000 $\times g$ for 5 minutes at 4° C. The cell pellet was washed twice with ice-cold PBS (pH 7.4), followed by a single wash with ice-cold caspase buffer (20 mM PIPES, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1% CHAPS, 250 mM sucrose, pH 7.2). After centrifugation, the cells were resuspended in two volumes of ice-cold complete caspase buffer, which was supplemented with protease inhibitors (100 mM PMSF, 20 μM leupeptin, and 0.3 μM aprotinin). The cells were then transferred to a 2-mL Dounce homogenizer. After incubating on ice for 15 minutes, the cells were disrupted with 50 strokes using a B-type pestle (Fisher Scientific Ltd., Nepean, ON, Canada). Cell disruption (>95%) was confirmed by examining a 5 μL aliquot of the suspension under a light microscope after staining with Trypan blue. The nuclei were removed by centrifugation at 1000 $\times g$ for 10 minutes at 4° C. Polypeptide concentrations were determined using a BCA protein assay kit (Pierce Chemical Co., Rockford, Ill.), and the resultant suspension was incubated with either HIV protease or casp8p41 polypeptide.

[0093] For Western blot analysis, 50-200 μg of cytosolic polypeptides were fractionated on 10% or 15% polyacrylamide gels and transferred onto PVDF membranes (Millipore, Bedford, Mass.) for 3 hours at 100 V in transfer buffer (25 mM Tris, 192 mM glycine). The membranes were blocked by incubating them overnight at 4° C. or 2 hours at room temperature in TBS buffer (20 mM Tris, 150 mM NaCl, 0.05% Tween, pH 7.5) containing 2% BSA. The membranes were then washed five times with TBS buffer and blotted for 1 hour at room temperature with the following primary antibodies: monoclonal anti-caspase-8 (Biosource International, Camarillo, Calif.), anti-caspase-9 (Medical & Biological Laboratories Co., Watertown, Mass.), goat anti-BID (Santa Cruz Biotechnology), anti-cytochrome c and anti-PARP (BD Pharmingen, Mississauga, ON, Canada). The blots were washed five times with TBS and developed with HRP-linked secondary antibodies: sheep anti-mouse IgG, donkey anti-rabbit Ig (Amersham Pharmacia, Oakville, ON, Canada), and anti-goat IgG (Santa Cruz Biotechnology). All of the blots were developed using SuperSignal (Pierce, Rockford, Ill.), an enhanced chemiluminescence method, according to the manufacturer's protocol.

[0094] Adding either casp8p41 polypeptide or HIV protease to cytosols from Jurkat T cells resulted in cleavage of Bid to p15 tBid, release of cytochrome c from the mitochondrial fraction into the cytosol, and cleavage of caspase-9 and PARP (FIGS. 2A and 2F). The effects produced by casp8p41 polypeptide and HIV protease were indistinguishable. These findings indicated that casp8p41 polypeptide is able to initiate apoptosis in a manner similar to HIV protease.

[0095] The effect of transient expression of casp8p41 polypeptide in HeLa cells was investigated. HeLa cells were purchased from ATCC and maintained in Dulbecco's Modified Eagle Medium (DMEM; GIBCO) supplemented with

10% (v/v) FBS, 1% penicillin and streptomycin, and 2 mM L-glutamine. The cells were incubated at 37° C. in a humidified atmosphere containing 5% CO₂ and 95% air. Exponentially growing cells were seeded at 2500-5000 cells/well in a 96-well plate. The cells were transfected with a DNA plasmid expressing GFP (pEGFPC1, BD Biosciences Clontech, Palo Alto, Calif.), or with a plasmid expressing casp8p41 polypeptide as a fusion to the C-terminus of GFP (pEGFPC1casp8p41) using Fugene 6 (2 µL per µg DNA), according to the manufacturer's protocol. The pEGFPC1casp8p41 plasmid was constructed by inserting the gene sequence for the full length procaspase-8 protein into the BamHI site of pEGFPC1 and then using site directed mutagenesis to change the Phe at 356 to a stop codon. The plasmids were purified by centrifugation on a CsCl gradient prior to transfection.

[0096] HeLa cells transfected with pEGFPC1 or pEGFPC1casp8p41 were analyzed by confocal microscopy following staining with DAPI to visualize cell nuclei and TUNEL staining to detect apoptosis. Cells treated with camptothecin or DNase I were included as controls. Transient expression of GFPcasp8p41 in HeLa cells caused TUNEL-positive apoptosis of GFP-positive cells, but not GFP-negative cells. GFP-positive cells transfected with the GFP control vector were also negative for TUNEL (FIG. 2B). These observations indicated that casp8p41 polypeptide initiated apoptosis in cells in which it was expressed, but did not cause apoptosis of bystander cells.

[0097] Cells transfected with pEGFPC1 and pEGFPC1casp8p41 were also subjected to Annexin-V PE, active caspase-3, and TUNEL staining and analyzed for cell death by flow cytometry, gating specifically on GFP-positive cells. To perform the annexin-V staining assay, 1×10⁶ cells were harvested, washed, and stained with 2 µL annexin-V PE (BD Pharmingen, San Diego, Calif.) at 37° C. for 20 minutes. GFP and annexin-V PE double-positive cells were analyzed by flow cytometry at 30,000 events per sample. TUNEL staining for detection of apoptosis was performed according to the manufacturer's protocol (Roche, Nutley, N.J.). Flow cytometric analyses indicated that casp8p41 polypeptide induces TUNEL positivity and active caspase-3 expression (FIG. 2C) in a time-dependent manner (FIG. 2D).

[0098] Primary human T cells were tested for their response to expression of casp8p41 polypeptide by transfecting cells with a vector encoding casp8p41 polypeptide, or with a control vector encoding glycogen synthase kinase 3β (GSK3β; Kim et al., *J Biol Chem.*, 278:13995-14001 (2003)). PBL from HIV-negative donors were isolated and transfected with 2 µg/10×10⁶ cells with pcDNA3 HA GSK3β (Ougolkov et al., *Cancer Res.*, 65:2076-2081 (2005)) or pcDNA3 HA casp8p41 using nucleofectin (AMAXA, MD) and program U14. Transfected cells were analyzed for changes in viability by light scatter or for apoptosis by TUNEL staining.

[0099] While transfection of primary T cells with the GSK3β vector induced detectable apoptosis, transfection with the vector encoding casp8p41 polypeptide induced a significantly greater level of apoptosis (FIG. 2E). These results confirmed that casp8p41 polypeptide is proapoptotic in T cells, and suggested that it is a potent death stimulus.

Example 4

Developing an Anti-casp8p41 Antibody

[0100] During death receptor-initiated apoptosis, procaspase-8 is cleaved through induced proximity autoactivation

(Boatright et al., *Mol. Cell*, 11:529-41 (2003)). This process generates a p43 fragment of procaspase-8 by cleavage after amino acid Asp374 (Thornberry and Molineaux, *Protein Sci.*, 4:3-12 (1995)). The process whereby the p43 fragment of procaspase-8 is generated is distinct from the cleavage event that generates casp8p41 polypeptide. Since subsequent processing of caspase-8 is not known to induce cleavage at residues F355 and F356, the neopeptide which is generated at the carboxyl terminus of the casp8p41 fragment should not be generated during caspase-8 processing that does not involve HIV protease. To investigate this possibility, the carboxyl terminus of the casp8p41 polypeptide was used as an immunogen to generate a monoclonal antibody directed against the casp8p41 fragment.

[0101] A peptide corresponding to the C-terminal end of the caspase-8 p41 polypeptide (CPSLAGKPKVF; SEQ ID NO:3) was synthesized and linked to KLH via the N-terminal cysteine. An anti-casp8p41 monoclonal antibody was produced as described elsewhere (de StGroth and Scheidegger, *J. Immunol. Methods*, 35:1-21 (1980)). Initial screening was done by ELISA using the full-length antigen peptide. Subsequent screening and selection of hybridomas was completed using a peptide consisting of a seven alanine leader and the four C-terminal amino acids of the antigen peptide (AAAAAAAPKVF; SEQ ID NO:4). The selected clones were then screened by immunofluorescence and Western blotting to ensure specificity for the p41 fragment of caspase-8.

[0102] HeLa cells were transfected with a plasmid expressing GFP or with a plasmid expressing full-length caspase-8 polypeptide, casp8p43 polypeptide, or casp8p41 polypeptide as a fusion to the C-terminus of GFP (designated GFP FLcasp8, GFPcasp8p43, and GFPcasp8p41, respectively). To generate the GFP FLcasp8 plasmid, the full coding sequence of the human procaspase-8 gene was cloned into the BamHI site of pEGFPC1 (BD Biosciences Clontech). The GFPcasp8p43 and GFPcasp8p41 constructs were created by inserting a stop codon at amino acid 375 or 356, respectively, using the QuikChange® site-directed mutagenesis kit (Stratagene).

[0103] Lysates from the transfected cells were analyzed by immunoblotting using anti-casp8p41 or anti-GFP antibodies. Only cells transfected with GFPcasp8p41 contained polypeptide that was recognized by the casp8p41 antibody, whereas all cells contained polypeptide that was detected by the anti-GFP antibody (FIG. 3A). HeLa cells transfected with GFPcasp8p41, GFP FLcasp8, or GFPcasp8p43 were also analyzed by immunofluorescence using either the casp8p41 monoclonal antibody or an isotype control antibody along with PE-conjugated secondary anti-mouse immunoglobulin antibodies. Only those cells transfected with a plasmid expressing casp8p41 polypeptide and stained with the casp8p41 antibody were PE positive (FIG. 3B). These results indicated that the anti-casp8p41 monoclonal antibody recognized casp8p41 polypeptide, but not casp8p43 polypeptide or full-length procaspase-8 polypeptide, by immunoblotting (FIG. 3A) as well as immunohistochemistry (FIG. 3B).

Example 5

Analyzing casp8p41 Polypeptide in HIV Infected Cells In Vitro

[0104] To determine whether casp8p41 is produced specifically as a consequence of HIV-PR activity, as opposed to

being produced as a consequence of apoptotic processing of procaspase 8, casp8p41 expression was assessed following HIV-PR transfection in the presence or absence of HIV-PR inhibitor, Nelfinavir, or the pan-caspase inhibitor, z-VAD-fmk. Jurkat T cells were transfected with 1 μ g of pEYFP-protease per 10^7 cells using a square wave electroporator (BTX) at 320 V for 10 msec. Immediately following transfection, 7 μ M Nelfinavir or 20 μ M Z-VAD-fmk was added. The following morning, casp8p41 was assessed by flow cytometry. Casp8p41 was detectable in the HIV-PR transfected cells, and inhibiting protease activity abrogated casp8p41 production (FIG. 3C). In contrast, pan-caspase inhibition did not alter casp8p41 production, indicating that HIV protease, but not caspase processing, is required for casp8p41 production.

[0105] It was determined whether casp8p41 is generated in response to other apoptotic stimuli. Jurkat T cells (10^6) were treated with 10 μ M camptothecin, 100 ng/mL SuperKiller-TRAIL™ (Axxora), 250 ng/mL anti-Fas antibody CH-11 (Upstate Cell Signaling Solutions), 50 ng/mL TNF- α (R&D Systems) plus 5 μ g/mL cycloheximide, 2 μ M HIV Tat (NIH AIDS Research and Reference Reagent Program), 1 μ g/mL of HIV gp120 (ImmunoDiagnostic), or vehicle controls for 8 hours at 37° C. For Vpr-induced apoptosis, Jurkat T cells were incubated with isotonic glucose-Hepes buffer (2.4% glucose, 13 mM Hepes, 68 mM NaCl, 1.3 mM KCl, 4 mM Na₂HPO₄, and 0.7 mM KH₂PO₄, pH 7.2) alone or containing 10 μ M of Vpr-derived peptide (amino acids 61-75; NIH AIDS Research and Reference Reagent Program) for 4 hours at 37° C. After the incubation, cells were washed in PBS and incubated overnight at 37° C. After incubation for the indicated times, cells were fixed in 2% paraformaldehyde at 4° C. overnight. To determine the presence of casp8p41 on apoptotic cells, cells were permeabilized with PBS+0.1% NP-40 on ice for two minutes. Cells were then incubated with the mouse anti-casp8p41 antibody, followed by PE-labeled goat anti-mouse antibody (Becton Dickinson ImmunoCytometry) and FITC-labeled rabbit anti-active caspase-3 antibody.

[0106] Treatment of cells with TNF- α , TRAIL, and Fas ligation, stimuli that induce caspase-8 dependent apoptosis, did indeed induce apoptosis, as determined by activation of caspase-3. However, these stimuli did not generate casp8p41 immunoreactivity (FIG. 3D). The HIV proteins gp120, Tat, and Vpr induce apoptosis and have been implicated in HIV-induced T-cell death.

[0107] Stimulation of Jurkat cells with these proteins resulted in active caspase-3 staining, but casp8p41 was not detected. Likewise, casp8p41 was not produced by induction of apoptosis using camptothecin. To test whether casp8p41 could be detected in cells experimentally infected with HIV, HIV-infected cells were analyzed for casp8p41 and active caspase 3 three days following infection. Approximately 25% of cells were apoptotic (active caspase-3+), and casp8p41 was detected in a similar percentage of cells. Thus, casp8p41 is a selective marker of HIV protease-induced apoptosis that is not generated by death-receptor signaling, or by other stimuli that have been implicated in HIV-associated T cell death. Further, since casp8p41 is readily detectable in experimental HIV infection, this stimulus may be relevant to killing of infected cells.

[0108] To determine whether casp8p41 polypeptide is generated during infection with HIV, Jurkat T cells acutely infected with HIV TUB were analyzed by flow cytometry for p24 polypeptide and casp8p41 polypeptide. Casp8p41 immu-

noreactivity was observed in Jurkat T cells infected with HIV IIIb, but not in mock-infected control cells, indicating that HIV protease-mediated cleavage of procaspase-8 had occurred (FIG. 4A). Importantly, casp8p41 staining was observed exclusively in cells coexpressing p24, which is also a product of HIV protease-mediated processing. Thus, casp8p41 reactivity was only detected in cells having evidence of protease activity and direct HIV infection. In these infections, casp8p41 immunoreactivity varied directly with both the proportion of cells expressing p24 (FIG. 4A) and with cell death (FIG. 4B). These results suggested that infection, death, and the presence of casp8p41 polypeptide were linked.

[0109] This association was directly assessed by analyzing the proportion of cells positive for casp8p41 polypeptide that was apoptotic. If casp8p41 polypeptide were not responsible for death of infected cells, then the proportion of dying cells expressing casp8p41 polypeptide would be expected to be similar to the proportion of viable cells expressing casp8p41 polypeptide. Jurkat T cells acutely infected with HIV were analyzed on day 7 after infection for casp8p41 positivity and for apoptosis using the TUNEL assay. In these cultures, fewer than 10% of the casp8p41 polypeptide negative cells were TUNEL positive, whereas 92% of casp8p41 polypeptide positive cells were apoptotic (FIG. 4C).

[0110] Together with the data indicating that casp8p41 polypeptide can induce apoptotic signaling in a cell-free system, and the data demonstrating that expression of casp8p41 polypeptide alone can initiate apoptosis, these findings demonstrated that casp8p41 polypeptide is a cause of death of cells infected with HIV in vitro.

Example 6

Analyzing casp8p41 Production in HIV-Induced Cell Death

[0111] To assess the relative contribution of HIV-PR cleavage of procaspase 8 to the overall killing of T cells acutely infected with HIV, caspase-8 deficient I9.2 cells were stably transfected with a vector construct encoding full-length wild-type caspase 8 (casp8 WT), or full-length caspase 8 with the F355R, F356N mutations (casp8 RN; FIG. 5A). Since these cells have a low level of CD4 expression, robust HIV infection is not possible. Therefore, these cells were infected with VSV-G-pseudotyped HW instead. VSV-G infections were performed using an MOI of 1.0, as described elsewhere (Lum et al., *J Clin Invest.*, 111:1547-1554 (2003)). Infected cells were analyzed for viability (FIG. 5B), cell number (FIG. 5C), and casp8p41 expression (FIG. 5D). Cell viability was assessed using a cell titer glow luminescent assay (Promega, Madison, Wis.), according to the manufacturer's instructions. Using this assay, viability is determined based on quantitation of ATP as a marker of metabolically active cells.

[0112] Infection of I9.2 cells transfected with the vector construct encoding wild-type caspase 8 resulted in high levels of death in cells expressing casp8p41. Infection of I9.2 cells transfected with the vector construct encoding caspase 8 with F355R, F356N mutations resulted in less casp8p41 production and less VSV-G HIV-induced death. These results are in agreement with the observation that the casp8 F355R, F356N mutant is less susceptible to cleavage by HIV protease (FIG. 1D). Thus, introduction of a mutation in procaspase-8, which reduces the amount of casp8p41 polypeptide produced, reduces the amount of HIV-induced cell death.

Example 7

Analyzing casp8p41 Polypeptide in Cells from HIV Infected Patients

[0113] The association between viral replication, casp8p41 polypeptide expression, and apoptosis was assessed in cells from HIV-infected patients. Peripheral blood lymphocytes (PBLs) from HIV-infected patients or HIV-negative controls were collected following informed consent, harvested using Ficoll hypaque, and analyzed for p24 and casp8p41 positivity. PBLs (1×10^5 cells) were fixed with 2% paraformaldehyde in PBS and then permeabilized by incubation in PBS with 0.1% NP40 on ice for 2 minutes. Casp8p41 antibodies were added to the permeabilized cells, followed by addition of PE-labeled secondary antibodies (Becton Dickinson Immunocytometry Systems, San Jose, Calif.) and then anti-p24-FITC antibodies. Flow cytometry was performed using a FACScan (Becton Dickinson Immunocytometry Systems), and analysis was done using CellQuest software.

[0114] A small proportion of cells are physically infected with HIV. Consistent with this, a minority of cells were casp8p41 positive in bulk PBL populations. In patients with suppressed levels of viral replication, less than 2% of cells contained casp8p41. In patients with greater levels of viral replication, greater levels of casp8p41 were detected (FIG. 6A). In cells co-stained for p24 as a marker of cellular infection, the majority of p24 positive were also casp8p41 positive, and the majority of casp8p41 positive cells were p24 positive (FIG. 6B, top). Cells from HIV-negative patients did not contain p24 or casp8p41 polypeptides. Cells from patients with <50 copies of plasma viremia had far fewer casp8p41+ cells than cells from patients with active viral replication, indicating both that reducing viral replication reduces production of casp8p41, and that undetectable viremia is not equivalent to absent replication (FIG. 6B, top). Consistent with the cell-free data, as well as the transfection and in vitro infection data described herein, cells containing casp8p41 were apoptotic as determined by active caspase-3 staining (FIG. 6B, bottom).

[0115] Both in vitro and in vivo, some casp8p41+ cells did not stain for p24. It is possible that this occurs when intracellular infection is insufficient to generate detectable p24, but does produce detectable casp8p41. This possibility was assessed by analyzing the proportion of p24+ cells that contain casp8p41 in patients with varying degrees of viral replication. In patients with undetectable viral replication, rare p24+ cells were observed, demonstrating that suppressive antiviral therapy does not totally eliminate intracellular replication. Casp8p41 polypeptide was present in a third of those p24+ cells (FIG. 6C). However, as viral replication increased, the proportion of p24+ cells containing casp8p41 increased. In some cases, virtually all p24+ cells contained casp8p41. Logistic regression confirmed the striking direct association between viral replication and the proportion of p24+ cells containing casp8p41.

[0116] The involvement of casp8p41 polypeptide in killing of cells in lymphatic tissues from patients infected with HIV was evaluated. Freshly frozen tissues were stained with DAPI, anti-casp8p41-Alexafluor 555 antibodies, and anti-p24-FITC or anti-active caspase-3 antibodies. Laser-scanning confocal microscopy was performed using a Zeiss LSM-510 laser scanning confocal microscope (Carl Zeiss Inc., Thornwood, N.Y.). Images were saved at eight bits per chan-

nel and analyzed for fluorescent interaction using the computer analysis package ANALYZE (Mayo Foundation, Rochester, Minn.).

[0117] Polychromatic flow cytometry was used to determine how casp8p41 expression is localized within individual T cell subsets in vivo. Peripheral blood mononuclear cells (PBMC) from HIV-infected and uninfected individuals were stained with monoclonal antibodies against CD3, CD4, CD8, CD45RO, CD27, p41, CD14, and CD16. Monoclonal antibodies used for phenotypic characterization of T-cell subsets were anti-CD19 Cascade Blue, anti-CD14 Cascade Blue, anti-CD27 PE, anti-p41 Alexa 647, anti-CD45RO FITC (Coulter), CD3 Cy7APC, CD8 QDot705, CD4 Cy5.5PE and (Caltag). Unconjugated antibodies against CD19, CD14, and CD8 were obtained from BD Pharmingen, and p41 antibody was produced, purified and then conjugated with the Alexa 647 (Invitrogen) using standard protocols (described at dmr.cotn/abcon on the World Wide Web). Qdot conjugations were performed as described elsewhere (Chattopadhyay et al., *Nature Medicine* (2006)). All sorts were performed on stained cells fixed with 1% paraformaldehyde (PFA; Electron Microscopy Sciences, Ft. Washington, Pa.) using a modified FACS Aria (BD). Instrument set up was performed according to manufacturer's instructions. All sorts were performed at 25 PSI. Instrument compensation was performed using antibody-capture beads (BD Pharmingen) stained singly with individual antibodies used in the test samples.

[0118] A representative dot plot is presented in FIG. 6D. The highest frequency of casp8p41+ cells belonged to the CD27+ memory CD4+ T cell subset (Table 1), consistent with other studies demonstrating that CD27+ memory CD4+ T cells represent the most frequently infected T cell subset in vivo (Brenchley et al., *J. Virol.*, 78:1160-1168 (2004)). The frequency of casp8p41+ cells in HIV-uninfected individuals was negligible. Further, small numbers of casp8p41+ memory CD4+ T cells could be sorted from all HIV+ individuals. Quantitative PCR was performed to analyze viral DNA, based on the gating scheme presented in FIG. 6D. An ABI7700 (Perkin-Elmer, Norwalk, Conn.) instrument was used to quantify HIV DNA, as described elsewhere (Douek et al., *Nature*, 417:95-98 (2002)). To quantify cell number in each reaction, quantitative PCR was performed simultaneously for albumin gene copy number as described elsewhere (Douek et al., *Nature*, 417:95-98 (2002)). Standards were constructed for absolute quantification of gag and albumin copy number, and were validated with sequential dilutions of 8E5 and Ach2 cell lysates containing one copy of gag per cell. Duplicate reactions were analyzed and template copies calculated using ABI7700 software. In all cases, viral DNA was present in casp8p41+ memory CD4+ T cells (Table 1).

TABLE 1

Frequency of casp8p41 in CD4+ T cell subsets and CD8+ T cells.						
Subject	CD4	VL	% memory CD4 casp8p41+	% naive CD4 casp8p41+	% CD8 casp8p41+	% of memory CD4 that contain viral DNA
1	552	22,000	0.06	0.01	≤0.009	0.1
2	145	35,000	0.09	0.03	≤0.009	6.1
3	205	54,000	0.1	0.04	≤0.009	0.51
4	752	18,000	0.07	0.02	≤0.009	0.97

TABLE 1-continued

Frequency of casp8p41 in CD4+ T cell subsets and CD8+ T cells.						
Subject	CD4	VL	% memory CD4 casp8p41+	% naive CD4 casp8p41+	% CD8 casp8p41+	% of memory CD4 that contain viral DNA
5	HIV-		≤0.009	≤0.009	≤0.009	
6	HIV-		≤0.009	≤0.009	≤0.009	
7	HIV-		≤0.009	≤0.009	≤0.009	
8	HIV-		≤0.009	≤0.009	≤0.009	

[0119] No p24 or casp8p41 reactivity was evident in tissues from RN-negative patients (FIG. 7A). In contrast, tissues from HIV-infected donors in whom viral replication was not suppressed showed diffuse and widespread p24 and casp8p41 immunoreactivity that was usually colocalized (FIG. 7A). In rare cases, however, p24-positive cells were present that were negative for casp8p41 polypeptide. In no instances were casp8p41-positive cells present that were p24 negative. In tissues of HIV-infected patients with suppressed levels of viral replication, p24 staining was rare, but colocalized with casp8p41 staining when present, indicating protease activity (FIG. 7A). Moreover, casp8p41 polypeptide was observed to colocalize with active caspase-3 polypeptide, indicating that casp8p41-positive cells are apoptotic (FIG. 7B).

Example 8

Linking casp8p41 Polypeptide and NFκB activation

[0120] Activation of the polypeptide signaling cascade resulting in up-regulation of NFκB dependant genes is important for HIV replication. In fact, HIV replication has been shown to be dependant on NFκB activation. NFκB activation is also an important factor in the expression of many anti-apoptotic cellular polypeptides. Therefore, an increase in activation of NFκB-mediated transcription can lead to an increase in HIV replication along with an increase in expression of polypeptides that keep the cell alive. Although HIV infection ultimately leads to cell death in the majority of cases, increases in NFκB activation can result in an increase in HIV production prior to cell death.

[0121] Using an over-expression system, caspase-8 polypeptide was found to increase NFκB activation. Importantly, casp8p41 polypeptide, the HIV protease-induced

cleavage product of caspase-8 polypeptide, activated NFκB-mediated transcription two-fold more than full-length caspase-8 polypeptide. These observations indicated that HIV increases its own transcription and replication as it kills the cell it has infected.

Example 9

Screening HIV Positive Blood Using an anti-casp8p41 Monoclonal Antibody

[0122] The availability of an anti-casp8p41 antibody offers clinicians the opportunity to design optimal treatment therapies for their HIV patients. Initial, pretreatment flow cytometry analysis comparing the level of casp8p41 positivity with HIV p24 antigen expression in CD4⁺ cells can be helpful in determining the rate at which the virus will deplete CD4⁺ cells. A high casp8p41 polypeptide to HIV p24 polypeptide ratio may indicate a more rapid depletion of CD4⁺ cells and may warrant a more aggressive treatment approach. Conversely, a low casp8p41 polypeptide to HIV p24 polypeptide ratio may indicate a less aggressive virus, especially when coupled with a higher than usual CD4⁺ count. This may also help identify "discordant" patients who have a much better prognosis.

[0123] Within days after beginning treatment, analysis of patient blood for casp8p41 polypeptide using flow cytometry indicates the effectiveness of the therapy prescribed and, when warranted, allows for a change in medication much sooner than waiting to assess the effectiveness of the treatment based on CD4⁺ cell number. The effectiveness of an HIV treatment can also be assessed by analyzing blood samples with an ELISA using the anti-casp8p41 antibody.

[0124] The casp8p41 antibody may also be useful in designing protease inhibitors that are more effective in blocking the specific activity of HIV protease against caspase-8, which initiates apoptosis in infected cells.

Other Embodiments

[0125] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 16

<210> SEQ ID NO 1

<211> LENGTH: 479

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Met Asp Phe Ser Arg Asn Leu Tyr Asp Ile Gly Glu Gln Leu Asp Ser
1 5 10 15

Glu Asp Leu Ala Ser Leu Lys Phe Leu Ser Leu Asp Tyr Ile Pro Gln
20 25 30

-continued

Arg	Lys	Gln	Glu	Pro	Ile	Lys	Asp	Ala	Leu	Met	Leu	Phe	Gln	Arg	Leu	35	40	45	
Gln	Glu	Lys	Arg	Met	Leu	Glu	Glu	Ser	Asn	Leu	Ser	Phe	Leu	Lys	Glu	50	55	60	
Leu	Leu	Phe	Arg	Ile	Asn	Arg	Leu	Asp	Leu	Leu	Ile	Thr	Tyr	Leu	Asn	65	70	75	80
Thr	Arg	Lys	Glu	Glu	Met	Glu	Arg	Glu	Leu	Gln	Thr	Pro	Gly	Arg	Ala	85	90	95	
Gln	Ile	Ser	Ala	Tyr	Arg	Val	Met	Leu	Tyr	Gln	Ile	Ser	Glu	Glu	Val	100	105	110	
Ser	Arg	Ser	Glu	Leu	Arg	Ser	Phe	Lys	Phe	Leu	Leu	Gln	Glu	Glu	Ile	115	120	125	
Ser	Lys	Cys	Lys	Leu	Asp	Asp	Asp	Met	Asn	Leu	Leu	Asp	Ile	Phe	Ile	130	135	140	
Glu	Met	Glu	Lys	Arg	Val	Ile	Leu	Gly	Glu	Gly	Lys	Leu	Asp	Ile	Leu	145	150	155	160
Lys	Arg	Val	Cys	Ala	Gln	Ile	Asn	Lys	Ser	Leu	Leu	Lys	Ile	Ile	Asn	165	170	175	
Asp	Tyr	Glu	Glu	Phe	Ser	Lys	Glu	Arg	Ser	Ser	Ser	Leu	Glu	Gly	Ser	180	185	190	
Pro	Asp	Glu	Phe	Ser	Asn	Gly	Glu	Glu	Leu	Cys	Gly	Val	Met	Thr	Ile	195	200	205	
Ser	Asp	Ser	Pro	Arg	Glu	Gln	Asp	Ser	Glu	Ser	Gln	Thr	Leu	Asp	Lys	210	215	220	
Val	Tyr	Gln	Met	Lys	Ser	Lys	Pro	Arg	Gly	Tyr	Cys	Leu	Ile	Ile	Asn	225	230	235	240
Asn	His	Asn	Phe	Ala	Lys	Ala	Arg	Glu	Lys	Val	Pro	Lys	Leu	His	Ser	245	250	255	
Ile	Arg	Asp	Arg	Asn	Gly	Thr	His	Leu	Asp	Ala	Gly	Ala	Leu	Thr	Thr	260	265	270	
Thr	Phe	Glu	Glu	Leu	His	Phe	Glu	Ile	Lys	Pro	His	Asp	Asp	Cys	Thr	275	280	285	
Val	Glu	Gln	Ile	Tyr	Glu	Ile	Leu	Lys	Ile	Tyr	Gln	Leu	Met	Asp	His	290	295	300	
Ser	Asn	Met	Asp	Cys	Phe	Ile	Cys	Cys	Ile	Leu	Ser	His	Gly	Asp	Lys	305	310	315	320
Gly	Ile	Ile	Tyr	Gly	Thr	Asp	Gly	Gln	Glu	Pro	Pro	Ile	Tyr	Glu	Leu	325	330	335	
Thr	Ser	Gln	Phe	Thr	Gly	Leu	Lys	Cys	Pro	Ser	Leu	Ala	Gly	Lys	Pro	340	345	350	
Lys	Val	Phe	Phe	Ile	Gln	Ala	Cys	Gln	Gly	Asp	Asn	Tyr	Gln	Lys	Gly	355	360	365	
Ile	Pro	Val	Glu	Thr	Asp	Ser	Glu	Glu	Gln	Pro	Tyr	Leu	Glu	Met	Asp	370	375	380	
Leu	Ser	Ser	Pro	Gln	Thr	Arg	Tyr	Ile	Pro	Asp	Glu	Ala	Asp	Phe	Leu	385	390	395	400
Leu	Gly	Met	Ala	Thr	Val	Asn	Asn	Cys	Val	Ser	Tyr	Arg	Asn	Pro	Ala	405	410	415	
Glu	Gly	Thr	Trp	Tyr	Ile	Gln	Ser	Leu	Cys	Gln	Ser	Leu	Arg	Glu	Arg	420	425	430	

-continued

Cys Pro Arg Gly Asp Asp Ile Leu Thr Ile Leu Thr Glu Val Asn Tyr
 435 440 445
 Glu Val Ser Asn Lys Asp Asp Lys Lys Asn Met Gly Lys Gln Met Pro
 450 455 460
 Gln Pro Thr Phe Thr Leu Arg Lys Lys Leu Val Phe Pro Ser Asp
 465 470 475

<210> SEQ ID NO 2
 <211> LENGTH: 355
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Asp Phe Ser Arg Asn Leu Tyr Asp Ile Gly Glu Gln Leu Asp Ser
 1 5 10 15
 Glu Asp Leu Ala Ser Leu Lys Phe Leu Ser Leu Asp Tyr Ile Pro Gln
 20 25 30
 Arg Lys Gln Glu Pro Ile Lys Asp Ala Leu Met Leu Phe Gln Arg Leu
 35 40 45
 Gln Glu Lys Arg Met Leu Glu Glu Ser Asn Leu Ser Phe Leu Lys Glu
 50 55 60
 Leu Leu Phe Arg Ile Asn Arg Leu Asp Leu Leu Ile Thr Tyr Leu Asn
 65 70 75 80
 Thr Arg Lys Glu Glu Met Glu Arg Glu Leu Gln Thr Pro Gly Arg Ala
 85 90 95
 Gln Ile Ser Ala Tyr Arg Val Met Leu Tyr Gln Ile Ser Glu Glu Val
 100 105 110
 Ser Arg Ser Glu Leu Arg Ser Phe Lys Phe Leu Leu Gln Glu Glu Ile
 115 120 125
 Ser Lys Cys Lys Leu Asp Asp Asp Met Asn Leu Leu Asp Ile Phe Ile
 130 135 140
 Glu Met Glu Lys Arg Val Ile Leu Gly Glu Gly Lys Leu Asp Ile Leu
 145 150 155 160
 Lys Arg Val Cys Ala Gln Ile Asn Lys Ser Leu Leu Lys Ile Ile Asn
 165 170 175
 Asp Tyr Glu Glu Phe Ser Lys Glu Arg Ser Ser Ser Leu Glu Gly Ser
 180 185 190
 Pro Asp Glu Phe Ser Asn Gly Glu Glu Leu Cys Gly Val Met Thr Ile
 195 200 205
 Ser Asp Ser Pro Arg Glu Gln Asp Ser Glu Ser Gln Thr Leu Asp Lys
 210 215 220
 Val Tyr Gln Met Lys Ser Lys Pro Arg Gly Tyr Cys Leu Ile Ile Asn
 225 230 235 240
 Asn His Asn Phe Ala Lys Ala Arg Glu Lys Val Pro Lys Leu His Ser
 245 250 255
 Ile Arg Asp Arg Asn Gly Thr His Leu Asp Ala Gly Ala Leu Thr Thr
 260 265 270
 Thr Phe Glu Glu Leu His Phe Glu Ile Lys Pro His Asp Asp Cys Thr
 275 280 285
 Val Glu Gln Ile Tyr Glu Ile Leu Lys Ile Tyr Gln Leu Met Asp His
 290 295 300
 Ser Asn Met Asp Cys Phe Ile Cys Cys Ile Leu Ser His Gly Asp Lys
 305 310 315 320

-continued

Gly Ile Ile Tyr Gly Thr Asp Gly Gln Glu Pro Pro Ile Tyr Glu Leu
325 330 335

Thr Ser Gln Phe Thr Gly Leu Lys Cys Pro Ser Leu Ala Gly Lys Pro
340 345 350

Lys Val Phe
355

<210> SEQ ID NO 3
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: C-terminal end of caspase-8 p41 polypeptide

<400> SEQUENCE: 3

Cys Pro Ser Leu Ala Gly Lys Pro Lys Val Phe
1 5 10

<210> SEQ ID NO 4
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Seven alanine amino acids and four c-terminal
amino acids of caspase-8 p41 polypeptide

<400> SEQUENCE: 4

Ala Ala Ala Ala Ala Ala Pro Lys Val Phe
1 5 10

<210> SEQ ID NO 5
<211> LENGTH: 522
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

Met Lys Ser Gln Gly Gln His Trp Tyr Ser Ser Ser Asp Lys Asn Cys
1 5 10 15

Lys Val Ser Phe Arg Glu Lys Leu Leu Ile Ile Asp Ser Asn Leu Gly
20 25 30

Val Gln Asp Val Glu Asn Leu Lys Phe Leu Cys Ile Gly Leu Val Pro
35 40 45

Asn Lys Lys Leu Glu Lys Ser Ser Ser Ala Ser Asp Val Phe Glu His
50 55 60

Leu Leu Ala Glu Asp Leu Leu Ser Glu Glu Asp Pro Phe Phe Leu Ala
65 70 75 80

Glu Leu Leu Tyr Ile Ile Arg Gln Lys Lys Leu Leu Gln His Leu Asn
85 90 95

Cys Thr Lys Glu Glu Val Glu Arg Leu Leu Pro Thr Arg Gln Arg Val
100 105 110

Ser Leu Phe Arg Asn Leu Leu Tyr Glu Leu Ser Glu Gly Ile Asp Ser
115 120 125

Glu Asn Leu Lys Asp Met Ile Phe Leu Leu Lys Asp Ser Leu Pro Lys
130 135 140

Thr Glu Met Thr Ser Leu Ser Phe Leu Ala Phe Leu Glu Lys Gln Gly
145 150 155 160

Lys Ile Asp Glu Asp Asn Leu Thr Cys Leu Glu Asp Leu Cys Lys Thr

-continued

165					170					175					
Val	Val	Pro	Lys	Leu	Leu	Arg	Asn	Ile	Glu	Lys	Tyr	Lys	Arg	Glu	Lys
			180					185					190		
Ala	Ile	Gln	Ile	Val	Thr	Pro	Pro	Val	Asp	Lys	Glu	Ala	Glu	Ser	Tyr
		195					200					205			
Gln	Gly	Glu	Glu	Glu	Leu	Val	Ser	Gln	Thr	Asp	Val	Lys	Thr	Phe	Leu
	210					215					220				
Glu	Ala	Leu	Pro	Gln	Glu	Ser	Trp	Gln	Asn	Lys	His	Ala	Gly	Ser	Asn
	225			230						235					240
Gly	Asn	Arg	Ala	Thr	Asn	Gly	Ala	Pro	Ser	Leu	Val	Ser	Arg	Gly	Met
			245						250					255	
Gln	Gly	Ala	Ser	Ala	Asn	Thr	Leu	Asn	Ser	Glu	Thr	Ser	Thr	Lys	Arg
		260					265						270		
Ala	Ala	Val	Tyr	Arg	Met	Asn	Arg	Asn	His	Arg	Gly	Leu	Cys	Val	Ile
		275					280					285			
Val	Asn	Asn	His	Ser	Phe	Thr	Ser	Leu	Lys	Asp	Arg	Gln	Gly	Thr	His
	290					295					300				
Lys	Asp	Ala	Glu	Ile	Leu	Ser	His	Val	Phe	Gln	Trp	Leu	Gly	Phe	Thr
	305			310						315				320	
Val	His	Ile	His	Asn	Asn	Val	Thr	Lys	Val	Glu	Met	Glu	Met	Val	Leu
			325						330					335	
Gln	Lys	Gln	Lys	Cys	Asn	Pro	Ala	His	Ala	Asp	Gly	Asp	Cys	Phe	Val
		340					345					350			
Phe	Cys	Ile	Leu	Thr	His	Gly	Arg	Phe	Gly	Ala	Val	Tyr	Ser	Ser	Asp
	355					360					365				
Glu	Ala	Leu	Ile	Pro	Ile	Arg	Glu	Ile	Met	Ser	His	Phe	Thr	Ala	Leu
	370					375					380				
Gln	Cys	Pro	Arg	Leu	Ala	Glu	Lys	Pro	Lys	Leu	Phe	Phe	Ile	Gln	Ala
	385			390					395					400	
Cys	Gln	Gly	Glu	Glu	Ile	Gln	Pro	Ser	Val	Ser	Ile	Glu	Ala	Asp	Ala
		405							410					415	
Leu	Asn	Pro	Glu	Gln	Ala	Pro	Thr	Ser	Leu	Gln	Asp	Ser	Ile	Pro	Ala
		420					425					430			
Glu	Ala	Asp	Phe	Leu	Leu	Gly	Leu	Ala	Thr	Val	Pro	Gly	Tyr	Val	Ser
	435					440						445			
Phe	Arg	His	Val	Glu	Glu	Gly	Ser	Trp	Tyr	Ile	Gln	Ser	Leu	Cys	Asn
	450					455					460				
His	Leu	Lys	Lys	Leu	Val	Pro	Arg	His	Glu	Asp	Ile	Leu	Ser	Ile	Leu
	465			470						475				480	
Thr	Ala	Val	Asn	Asp	Asp	Val	Ser	Arg	Arg	Val	Asp	Lys	Gln	Gly	Thr
		485						490					495		
Lys	Lys	Gln	Met	Pro	Gln	Pro	Ala	Phe	Thr	Leu	Arg	Lys	Lys	Leu	Val
		500						505					510		
Phe	Pro	Val	Pro	Leu	Asp	Ala	Leu	Ser	Leu						
		515					520								

<210> SEQ ID NO 6

<211> LENGTH: 303

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

-continued

Met	Ala	Asp	Glu	Gln	Gly	Cys	Ile	Glu	Glu	Gln	Gly	Val	Glu	Asp	Ser	1	5	10	15
Ala	Asn	Glu	Asp	Ser	Val	Asp	Ala	Lys	Pro	Asp	Arg	Ser	Ser	Phe	Val	20	25	30	
Pro	Ser	Leu	Phe	Ser	Lys	Lys	Lys	Lys	Asn	Val	Thr	Met	Arg	Ser	Ile	35	40	45	
Lys	Thr	Thr	Arg	Asp	Arg	Val	Pro	Thr	Tyr	Gln	Tyr	Asn	Met	Asn	Phe	50	55	60	
Glu	Lys	Leu	Gly	Lys	Cys	Ile	Ile	Ile	Asn	Asn	Lys	Asn	Phe	Asp	Lys	65	70	75	80
Val	Thr	Gly	Met	Gly	Val	Arg	Asn	Gly	Thr	Asp	Lys	Asp	Ala	Glu	Ala	85	90	95	
Leu	Phe	Lys	Cys	Phe	Arg	Ser	Leu	Gly	Phe	Asp	Val	Ile	Val	Tyr	Asn	100	105	110	
Asp	Cys	Ser	Cys	Ala	Lys	Met	Gln	Asp	Leu	Leu	Lys	Lys	Ala	Ser	Glu	115	120	125	
Glu	Asp	His	Thr	Asn	Ala	Ala	Cys	Phe	Ala	Cys	Ile	Leu	Leu	Ser	His	130	135	140	
Gly	Glu	Glu	Asn	Val	Ile	Tyr	Gly	Lys	Asp	Gly	Val	Thr	Pro	Ile	Lys	145	150	155	160
Asp	Leu	Thr	Ala	His	Phe	Arg	Gly	Asp	Arg	Cys	Lys	Thr	Leu	Leu	Glu	165	170	175	
Lys	Pro	Lys	Leu	Phe	Phe	Ile	Gln	Ala	Cys	Arg	Gly	Thr	Glu	Leu	Asp	180	185	190	
Asp	Gly	Ile	Gln	Ala	Asp	Ser	Gly	Pro	Ile	Asn	Asp	Thr	Asp	Ala	Asn	195	200	205	
Pro	Arg	Tyr	Lys	Ile	Pro	Val	Glu	Ala	Asp	Phe	Leu	Phe	Ala	Tyr	Ser	210	215	220	
Thr	Val	Pro	Gly	Tyr	Tyr	Ser	Trp	Arg	Ser	Pro	Gly	Arg	Gly	Ser	Trp	225	230	235	240
Phe	Val	Gln	Ala	Leu	Cys	Ser	Ile	Leu	Glu	Glu	His	Gly	Lys	Asp	Leu	245	250	255	
Glu	Ile	Met	Gln	Ile	Leu	Thr	Arg	Val	Asn	Asp	Arg	Val	Ala	Arg	His	260	265	270	
Phe	Glu	Ser	Gln	Ser	Asp	Asp	Pro	His	Phe	His	Glu	Lys	Lys	Gln	Ile	275	280	285	
Pro	Cys	Val	Val	Ser	Met	Leu	Thr	Lys	Glu	Leu	Tyr	Phe	Ser	Gln	290	295	300		

<210> SEQ ID NO 7

<211> LENGTH: 115

<212> TYPE: PRT

<213> ORGANISM: Pan troglodytes

<400> SEQUENCE: 7

Met	Asp	Phe	Ser	Arg	Asn	Leu	Tyr	Asp	Ile	Gly	Glu	Gln	Leu	Asp	Ser	1	5	10	15
Glu	Asp	Leu	Ala	Ser	Leu	Lys	Phe	Leu	Ser	Leu	Asp	Tyr	Ile	Pro	Gln	20	25	30	
Arg	Lys	Gln	Glu	Pro	Ile	Lys	Asp	Ala	Leu	Met	Leu	Phe	Gln	Arg	Leu	35	40	45	
Gln	Glu	Lys	Arg	Met	Leu	Glu	Glu	Ser	Asn	Leu	Ser	Phe	Leu	Lys	Glu	50	55	60	

-continued

Leu Leu Phe Arg Ile Asn Arg Leu Asp Leu Leu Ile Thr Tyr Leu Asn
65 70 75 80

Thr Arg Lys Glu Glu Met Glu Arg Glu Leu Gln Thr Pro Gly Arg Ala
85 90 95

Gln Ile Ser Ala Tyr Arg Trp Val Glu Thr Pro Ile Val Gly Leu Gly
100 105 110

Gly Val Gly
115

<210> SEQ ID NO 8
<211> LENGTH: 263
<212> TYPE: PRT
<213> ORGANISM: Pan troglodytes

<400> SEQUENCE: 8

Met Ala Asp Asp Gln Gly Cys Ile Glu Glu Gln Gly Val Glu Asp Ser
1 5 10 15

Ala Asn Glu Asp Ser Val Asp Ala Lys Pro Asp Arg Ser Ser Phe Val
20 25 30

Pro Ser Leu Phe Ser Lys Lys Lys Lys Asn Val Thr Met Arg Ser Ile
35 40 45

Lys Thr Thr Arg Asp Arg Val Pro Thr Tyr Gln Tyr Asn Met Asn Phe
50 55 60

Glu Lys Leu Gly Lys Cys Ile Ile Ile Asn Asn Lys Asn Phe Asp Lys
65 70 75 80

Val Thr Gly Met Gly Val Arg Asn Gly Thr Asp Lys Asp Ala Glu Ala
85 90 95

Leu Phe Lys Cys Phe Arg Ser His Gly Glu Glu Asn Val Ile Tyr Gly
100 105 110

Lys Asp Gly Val Thr Pro Ile Lys Asp Leu Thr Ala His Phe Arg Gly
115 120 125

Asp Arg Cys Lys Thr Leu Leu Glu Lys Pro Lys Leu Phe Phe Ile Gln
130 135 140

Ala Cys Arg Gly Thr Glu Leu Asp Asp Gly Ile Gln Ala Asp Ser Gly
145 150 155 160

Pro Ile Asn Asp Thr Asp Ala Asn Pro Arg Tyr Lys Ile Pro Val Glu
165 170 175

Ala Asp Phe Leu Phe Ala Tyr Ser Thr Val Pro Gly Tyr Tyr Ser Trp
180 185 190

Arg Ser Pro Gly Arg Gly Ser Trp Phe Val Gln Ala Leu Cys Ser Ile
195 200 205

Leu Glu Glu His Gly Lys Asp Leu Glu Ile Met Gln Ile Leu Thr Arg
210 215 220

Val Asn Asp Arg Val Ala Arg His Phe Glu Ser Gln Ser Asp Asp Pro
225 230 235 240

Arg Phe His Glu Lys Lys Gln Ile Pro Cys Val Val Ser Met Leu Thr
245 250 255

Lys Glu Leu Tyr Phe Ser Gln
260

<210> SEQ ID NO 9
<211> LENGTH: 234
<212> TYPE: PRT

-continued

<213> ORGANISM: Pan troglodytes

<400> SEQUENCE: 9

```

Met Lys Ser Gln Gly Gln His Trp Cys Ser Ser Ser Asp Lys Asn Cys
1      5      10      15
Lys Val Ser Phe Arg Glu Lys Leu Leu Ile Ile Asp Ser Asn Leu Gly
20      25      30
Val Gln Asp Val Glu Asn Leu Lys Phe Leu Cys Ile Gly Leu Val Pro
35      40      45
Asn Lys Leu Leu Glu Thr Ser Ser Ser Ala Ser Asp Val Phe Glu Pro
50      55      60
Phe Leu Ala Glu Asp Leu Leu Ser Glu Asp Asp Pro Phe Phe Leu Ala
65      70      75      80
Glu Leu Leu Tyr Ile Ile Arg Gln Lys Lys Leu Leu Gln His Leu Asn
85      90      95
Tyr Thr Lys Glu Glu Val Glu Arg Leu Leu Pro Thr Arg Gln Arg Val
100     105     110
Ser Leu Phe Arg Asn Leu Leu Tyr Glu Leu Ser Glu Gly Ile Asp Ser
115     120     125
Glu Asn Leu Lys Asp Met Ile Phe Leu Leu Lys Asp Ser Leu Pro Lys
130     135     140
Thr Glu Met Thr Ser Leu Ser Phe Leu Ala Phe Leu Glu Lys Gln Gly
145     150     155     160
Lys Ile Asp Glu Asp Asn Leu Thr Cys Leu Glu Asp Leu Cys Thr Thr
165     170     175
Val Val Pro Lys Leu Leu Arg Asn Ile Glu Lys Tyr Lys Arg Glu Lys
180     185     190
Ala Val Gln Ile Val Thr Pro Pro Val Asp Lys Glu Ala Glu Ser Tyr
195     200     205
Gln Gly Glu Glu Glu Leu Val Ser Gln Thr Asp Val Lys Thr Phe Leu
210     215     220
Glu Ala Leu Pro Val Gly Val Leu Ala Lys
225     230

```

<210> SEQ ID NO 10

<211> LENGTH: 48

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Oligonucleotide

<400> SEQUENCE: 10

```

cccaagctta tggactacaa agacgatgac ggtaccatgg acttcagc      48

```

<210> SEQ ID NO 11

<211> LENGTH: 68

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Oligonucleotide

<400> SEQUENCE: 11

```

ccgggccctt actacagatc ctcttctgag atgagttttt gttctctaga ttgatcagaa      60
gggaaaag                                     68

```

-continued

<210> SEQ ID NO 12
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

Arg Gly Tyr Cys Leu Ile Ile Asn Asn His Asn Phe Ala Lys
1 5 10

<210> SEQ ID NO 13
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

Lys Gly Ile Ile Tyr Gly Thr Asp Gly Gln Glu Ala Pro Ile Tyr Glu
1 5 10 15

Leu Thr Ser Gln Phe Thr Gly Leu Lys
20 25

<210> SEQ ID NO 14
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

Lys Val Phe Phe Ile Gln Ala Cys Gln Gly Asp Asn Tyr Gln Lys
1 5 10 15

<210> SEQ ID NO 15
<211> LENGTH: 2243
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

ggacgtcgag gcattacaat cgcgaaacca agccatagca tgaacacagcg agcttgcagc 60
ctcaccgacg agtctcaact aaaagggact cccggagcta ggggtgggga ctcggcctca 120
cacagtgagt gccggtatt ggacttttgt ccagtgcagc ctgagacaac aaggaccacg 180
ggaggagggtg taggagagaa gcgcgcgcaa cagcgatcgc ccagcaccia gtccgcttcc 240
aggctttcgg tttctttgcc tccatcttgg gtgcgccttc ccggcgctca ggggagcgaa 300
ggctgagggtg gcagcggcag gagagtccgg ccgcgacagg acgaactccc ccactggaaa 360
ggattctgaa agaaatgaag tcagccctca gaaatgaagt tgactgcctg ctggctttcc 420
tgttgactgg cccggagctg tactgcaaga cccttgtagg cttccctagt ctaagagtag 480
gatgtctgct gaagtcatcc atcagggtga agaagcactt gatacagatg agaaggagat 540
gctgctcttt ttgtgcggg agtttgctat agatgtggtt ccacctaatg tcagggacct 600
tctggatatt ttacgggaaa gagtaagct gtctgtcggg gacttggtg aactgctcta 660
cagagtgagg cgatttgacc tgctcaaacg tatcttgaag atggacagaa aagctgtgga 720
gacccacctg ctcaggaacc ctcacctgtt ttcggactat agagtgtga tggcagagat 780
tggtgaggat ttggataaat ctgatgtgtc ctcattaatt ttcctcatga aggattacat 840
gggccgaggc aagataagca aggagaagag tttcttgga cttgtggttg agttggagaa 900
actaaatttg gttgccccag atcaactgga tttattagaa aaatgcctaa agaacatcca 960
cagaatagac ctgaagacaa aaatccagaa gtacaagcag tctgttcaag gagcagggac 1020

-continued

```

aagttacagg aatgttctcc aagcagcaat ccaaaagagt ctcaaggatc cttcaataa 1080
cttcaggctc cataatggga gaagtaaaga acaaagactt aaggaacagc ttggcgctca 1140
acaagaacca gtgaagaaat ccattcagga atcagaagct tttttgcctc agagcatacc 1200
tgaagagaga tacaagatga agagcaagcc cctaggaatc tgcctgataa tcgattgcat 1260
tggcaatgag acagagcttc ttcgagacac cttcacttcc ctgggctatg aagtcagaa 1320
attcttgcac ctcagtatgc atggtatata ccagattctt ggccaatttg cctgtatgcc 1380
cgagcaccga gactacgaca gctttgtgtg tgtcctggtg agccgaggag gctcccagag 1440
tgtgtatggt gtggatcaga ctcactcagg gctccccctg catcacatca ggaggatgtt 1500
catgggagat tcattgccctt attctagcagg gaagccaaag atgtttttta ttcagaacta 1560
tgtggtgtca gagggccagc tggagaacag cagcctcttg gaggtggatg ggccagcgat 1620
gaagaatgtg gaattcaagg ctcagaagcg agggctgtgc acagttcacc gagaagctga 1680
cttcttcttg agcctgtgta ctgcggacat gtccctgtg gagcagtctc acagctcacc 1740
gtccctgtac ctgcagtgcc tctcccagaa actgagacaa gaaagaaaac gccactcct 1800
ggatcttcac attgaactca atggtacatc gtatgattgg aacagcagag tttctgcca 1860
ggagaaatat tatgtctggc tgcagcacac tctgagaaag aaacttatcc tctcctacac 1920
ataagaaacc aaaaggctgg gcgtagtggc tcacacctgt aatcccagca ctttgggagg 1980
ccaaggaggg cagatcactt caggtcagga gttcgagacc agcctggcca acatggtaaa 2040
cgctgtccct agtaaaaatg caaaaattag ctgggtgtgg gtgtgggtac ctgtgttccc 2100
agttacttgg gaggtcagag tgggaggatc ttttgaacc aggagttag ggtcatagca 2160
tgctgtgatt gtgcctacga atagccactg cataccaacc tgggcaatat agcaagatcc 2220
catctcttta aaaaaaaaaa aaa 2243

```

<210> SEQ ID NO 16

<211> LENGTH: 480

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

```

Met Ser Ala Glu Val Ile His Gln Val Glu Glu Ala Leu Asp Thr Asp
1           5           10          15

Glu Lys Glu Met Leu Leu Phe Leu Cys Arg Asp Val Ala Ile Asp Val
20          25          30

Val Pro Pro Asn Val Arg Asp Leu Leu Asp Ile Leu Arg Glu Arg Gly
35          40          45

Lys Leu Ser Val Gly Asp Leu Ala Glu Leu Leu Tyr Arg Val Arg Arg
50          55          60

Phe Asp Leu Leu Lys Arg Ile Leu Lys Met Asp Arg Lys Ala Val Glu
65          70          75          80

Thr His Leu Leu Arg Asn Pro His Leu Val Ser Asp Tyr Arg Val Leu
85          90          95

Met Ala Glu Ile Gly Glu Asp Leu Asp Lys Ser Asp Val Ser Ser Leu
100         105         110

Ile Phe Leu Met Lys Asp Tyr Met Gly Arg Gly Lys Ile Ser Lys Glu
115         120         125

Lys Ser Phe Leu Asp Leu Val Val Glu Leu Glu Lys Leu Asn Leu Val

```

130	135	140
Ala Pro Asp Gln Leu Asp Leu Leu Glu Lys Cys Leu Lys Asn Ile His 145 150 155 160		
Arg Ile Asp Leu Lys Thr Lys Ile Gln Lys Tyr Lys Gln Ser Val Gln 165 170 175		
Gly Ala Gly Thr Ser Tyr Arg Asn Val Leu Gln Ala Ala Ile Gln Lys 180 185 190		
Ser Leu Lys Asp Pro Ser Asn Asn Phe Arg Leu His Asn Gly Arg Ser 195 200 205		
Lys Glu Gln Arg Leu Lys Glu Gln Leu Gly Ala Gln Gln Glu Pro Val 210 215 220		
Lys Lys Ser Ile Gln Glu Ser Glu Ala Phe Leu Pro Gln Ser Ile Pro 225 230 235 240		
Glu Glu Arg Tyr Lys Met Lys Ser Lys Pro Leu Gly Ile Cys Leu Ile 245 250 255		
Ile Asp Cys Ile Gly Asn Glu Thr Glu Leu Leu Arg Asp Thr Phe Thr 260 265 270		
Ser Leu Gly Tyr Glu Val Gln Lys Phe Leu His Leu Ser Met His Gly 275 280 285		
Ile Ser Gln Ile Leu Gly Gln Phe Ala Cys Met Pro Glu His Arg Asp 290 295 300		
Tyr Asp Ser Phe Val Cys Val Leu Val Ser Arg Gly Gly Ser Gln Ser 305 310 315 320		
Val Tyr Gly Val Asp Gln Thr His Ser Gly Leu Pro Leu His His Ile 325 330 335		
Arg Arg Met Phe Met Gly Asp Ser Cys Pro Tyr Leu Ala Gly Lys Pro 340 345 350		
Lys Met Phe Phe Ile Gln Asn Tyr Val Val Ser Glu Gly Gln Leu Glu 355 360 365		
Asn Ser Ser Leu Leu Glu Val Asp Gly Pro Ala Met Lys Asn Val Glu 370 375 380		
Phe Lys Ala Gln Lys Arg Gly Leu Cys Thr Val His Arg Glu Ala Asp 385 390 395 400		
Phe Phe Trp Ser Leu Cys Thr Ala Asp Met Ser Leu Leu Glu Gln Ser 405 410 415		
His Ser Ser Pro Ser Leu Tyr Leu Gln Cys Leu Ser Gln Lys Leu Arg 420 425 430		
Gln Glu Arg Lys Arg Pro Leu Leu Asp Leu His Ile Glu Leu Asn Gly 435 440 445		
Tyr Met Tyr Asp Trp Asn Ser Arg Val Ser Ala Lys Glu Lys Tyr Tyr 450 455 460		
Val Trp Leu Gln His Thr Leu Arg Lys Lys Leu Ile Leu Ser Tyr Thr 465 470 475 480		

What is claimed is:

1. An antibody preparation comprising an antibody or fragment thereof, wherein said antibody or said fragment thereof binds to a polypeptide consisting of a sequence selected from the group consisting of the sequence set forth in SEQ ID NO:2 and the sequence set forth in SEQ ID NO:3 and does not bind to a human procaspase-8 polypeptide.

2. The antibody preparation of claim 1, wherein said antibody is a monoclonal antibody.

3. The antibody preparation of claim 1, wherein said antibody or said fragment thereof comprises a label selected from the group consisting of an enzyme, streptavidin, avidin, a fluorescent molecule, a luminescent molecule, a bioluminescent molecule, and a radioactive molecule.

4. An isolated cell that produces an antibody or fragment thereof, wherein said antibody or said fragment thereof binds to a polypeptide consisting of a sequence selected from the group consisting of the sequence set forth in SEQ ID NO:2 and the sequence set forth in SEQ ID NO:3 and does not bind to a human procaspase-8 polypeptide.

5. The isolated cell of claim 4, wherein said cell is a hybridoma.

6. The isolated cell of claim 4, wherein said antibody is a monoclonal antibody.

7. A method for determining whether or not a sample contains a casp8p41 polypeptide, said method comprising:

a) contacting said sample with an antibody or fragment thereof to form a complex between said casp8p41 polypeptide, if present in said sample, and said antibody or said fragment thereof, wherein said antibody or said fragment thereof binds to a polypeptide consisting of a sequence selected from the group consisting of the sequence set forth in SEQ ID NO:2 and the sequence set forth in SEQ ID NO:3 and does not bind to a human procaspase-8 polypeptide; and

b) determining the presence or absence of said complex, wherein said presence indicates that said sample contains said casp8p41 polypeptide, and wherein said absence indicates that said sample does not contain said casp8p41 polypeptide.

8. The method of claim 7, wherein said sample is blood.

9. The method of claim 7, wherein said determining step comprises performing an ELISA or flow cytometry.

10. A method for determining whether or not a treatment for an immunodeficiency virus infection decreases cell death, said method comprising determining whether or not the level of an IVP caspase polypeptide in a first sample from a mammal infected with an immunodeficiency virus is greater than or equal to the level of said IVP caspase polypeptide in a second sample from said mammal, wherein said first sample is from said mammal after said mammal received said treat-

ment, wherein said second sample is obtained at a later time than said first sample, wherein a level of said IVP caspase polypeptide in said first sample that is equal to or greater than the level of said IVP caspase polypeptide in said second sample indicates that said treatment decreases cell death, and wherein a level of said IVP caspase polypeptide in said first sample that is lower than the level of said IVP caspase polypeptide in said second sample indicates that said treatment does not decrease cell death.

11. The method of claim 10, wherein said immunodeficiency virus is human immunodeficiency virus.

12. The method of claim 10, wherein said mammal is a human.

13. The method of claim 10, wherein said IVP caspase polypeptide is a casp8p41 polypeptide.

14. The method of claim 10, wherein said sample is blood.

15. A method for monitoring an immunodeficiency virus infection, said method comprising determining whether or not the level of an IVP caspase polypeptide in a first sample from a mammal infected with an immunodeficiency virus is greater than the level of said IVP caspase polypeptide in a second sample from said mammal, wherein said second sample is from said mammal at a time later than that of said first sample, wherein a level of said IVP caspase polypeptide in said first sample that is greater than the level of said IVP caspase polypeptide in said second sample indicates suppression of said infection, and wherein a level of said IVP caspase polypeptide in said first sample that is lower than the level of said IVP caspase polypeptide in said second sample indicates progression of said infection.

16. A method for determining the prognosis of an immunodeficiency virus infection, said method comprising determining the level of an IVP caspase polypeptide in a mammal infected with an immunodeficiency virus, wherein a detectable level of said IVP caspase polypeptide indicates a poor prognosis, and wherein an undetectable level of said IVP caspase polypeptide indicates a good prognosis.

17. The method of claim 16, wherein said determining step comprises analyzing a sample from said mammal.

18. A method for detecting the presence of an immunodeficiency virus in a mammal, said method comprising determining whether or not an IVP caspase polypeptide is present within a mammal, wherein a detectable level of an IVP caspase polypeptide indicates the presence of an immunodeficiency virus, and wherein an undetectable level of said IVP caspase polypeptide indicates the absence of an immunodeficiency virus.

19. The method of claim 18, wherein said determining step comprises analyzing a sample from said mammal.

* * * * *

专利名称(译)	免疫缺陷病毒		
公开(公告)号	US20100062462A1	公开(公告)日	2010-03-11
申请号	US12/097473	申请日	2006-12-14
[标]申请(专利权)人(译)	BADLEY ANDREW D BREN GARY D 聂梓琳		
申请(专利权)人(译)	BADLEY ANDREW D BREN GARY D 聂梓琳		
当前申请(专利权)人(译)	梅奥基金会的医学教育和研究		
[标]发明人	BADLEY ANDREW D BREN GARY D NIE ZILIN		
发明人	BADLEY, ANDREW D. BREN, GARY D. NIE, ZILIN		
IPC分类号	G01N33/53 C07K16/00 C12N9/96 C12N5/00 C12Q1/34		
CPC分类号	C07K16/40		
优先权	60/750653 2005-12-14 US		
外部链接	Espacenet USPTO		

摘要(译)

该文献涉及检测，监测和预测免疫缺陷病毒感染的方法和材料。例如，用于确定哺乳动物（例如，人）是否具有免疫缺陷病毒感染（例如，HIV感染）的方法和材料，用于确定具有免疫缺陷病毒感染的哺乳动物是否正在改善的方法和材料，本发明提供了用于确定具有免疫缺陷病毒感染的哺乳动物是否具有晚期免疫缺陷病毒感染的方法和材料。

